Nervous system cancer
MONDO:0005872A primary or metastatic malignant neoplasm involving the nervous system.
Also known as: nervous system neoplasm, neural neoplasm, neural tumor, neural tumour, tumor of the nervous system, tumour of the nervous system, cancer of nervous system, malignant neoplasm of nervous system
4654 clinical trials for this condition and its sub-types, 17 tagged with Nervous system cancer itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Nervous system cancer
-
Central nervous system cancer 131 trials · 1,706 incl. sub-types
20 sub-types
- Malignant glioma 250 trials · 920 incl. sub-types Sub-types →
- Brain cancer 682 trials · 902 incl. sub-types Sub-types →
- Primary central nervous system lymphoma 92 trials · 103 incl. sub-types Sub-types →
- Central nervous system sarcoma 2 trials · 74 incl. sub-types Sub-types →
- Spinal cord cancer 21 trials · 57 incl. sub-types Sub-types →
- Central nervous system primitive neuroectodermal neoplasm 8 trials · 24 incl. sub-types Sub-types →
- Central nervous system Ewing sarcoma/peripheral primitive neuroectodermal tumor 1 trial · 22 incl. sub-types Sub-types →
- Malignant tumor of meninges 0 trials · 14 incl. sub-types Sub-types →
- Malignant adrenal gland pheochromocytoma 11 trials
- Central nervous system germinoma 2 trials · 4 incl. sub-types Sub-types →
- Central nervous system melanocytic neoplasm 1 trial · 4 incl. sub-types Sub-types →
- Central nervous system endodermal sinus tumor 0 trials · 1 incl. sub-types Sub-types →
- Choriocarcinoma of the central nervous system 0 trials Sub-types →
- Embryonal carcinoma of the central nervous system 0 trials Sub-types →
- Malignant carotid body paraganglioma 0 trials
- Malignant central nervous system mesenchymal, non-meningothelial neoplasm 0 trials Sub-types →
- Malignant jugulotympanic paraganglioma 0 trials
- Mixed germ cell tumor of central nervous system 0 trials Sub-types →
- Pheochromocytoma/paraganglioma syndrome 2 0 trials
- Pheochromocytoma/paraganglioma syndrome 5 0 trials
-
Sensory system cancer 0 trials · 232 incl. sub-types
7 sub-types
- Ocular cancer 10 trials · 168 incl. sub-types Sub-types →
- Tongue cancer 26 trials · 35 incl. sub-types Sub-types →
- Paranasal sinus cancer 4 trials · 24 incl. sub-types Sub-types →
- Nasal cavity cancer 5 trials · 14 incl. sub-types Sub-types →
- Auditory system cancer 0 trials · 2 incl. sub-types Sub-types →
- Malignant ear neoplasm 0 trials · 2 incl. sub-types Sub-types →
- Optic tract astrocytoma 0 trials Sub-types →
-
Cutaneous neuroendocrine carcinoma 78 trials
-
Peripheral nervous system cancer 0 trials · 67 incl. sub-types
18 sub-types
- Malignant peripheral nerve sheath tumor 36 trials · 38 incl. sub-types Sub-types →
- Malignant adrenal gland pheochromocytoma 11 trials
- Peripheral primitive neuroectodermal tumor 8 trials · 9 incl. sub-types Sub-types →
- Ganglioneuroma 5 trials Sub-types →
- Malignant cranial nerve neoplasm 0 trials · 4 incl. sub-types Sub-types →
- Granular cell cancer 1 trial · 2 incl. sub-types Sub-types →
- Malignant perineurioma 1 trial
- Adrenal gland ganglioneuroblastoma 0 trials
- Cauda equina cancer 0 trials
- Isolated melanotic schwannoma 0 trials
- Malignant carotid body paraganglioma 0 trials
- Malignant jugulotympanic paraganglioma 0 trials
- Malignant mediastinal neural neoplasm 0 trials
- Mediastinum neuroblastoma 0 trials Sub-types →
- Neurofibroma of gallbladder 0 trials
- Neurofibroma of the heart 0 trials
- Pheochromocytoma/paraganglioma syndrome 2 0 trials
- Pheochromocytoma/paraganglioma syndrome 5 0 trials
-
Ectomesenchymoma 1 trial
-
Adrenal gland neuroblastoma 0 trials
1 sub-type
- Adrenal gland ganglioneuroblastoma 0 trials
Most studied deeper sub-types
Showing the 400 most recently updated of 1052 trials in this tab.
-
Custom-Built immune cells take aim at a notorious cancer mutation
Cure OngoingResearchers are testing a new cell therapy called CRTKVA11-03 in people with advanced solid tumors that carry a specific KRAS G12V mutation and a matching immune marker called HLA-A*11:01. The treatment uses each patient's own T cells, engineered to recognize and attack cancer ce…
Phase 1 • Sponsor: Corregene Biotechnology Co., Ltd • Aim: Cure
Last updated Sep 19, 2026 00:00 UTC
-
Can a DNA vaccine train the immune system to hunt down HER3-Positive cancers?
Vaccine OngoingThis phase 1 trial tests an investigational DNA vaccine called pING-hHER3FL in people whose solid tumors have been surgically removed. The vaccine carries the genetic code for the HER3 protein, which is found on many cancer types, and aims to trigger a targeted immune response ag…
Phase 1 • Sponsor: Herbert Lyerly • Aim: Vaccine
Last updated Sep 04, 2026 00:00 UTC
-
New vaccine trial targets aggressive brain cancer
Vaccine OngoingThis early-phase trial tests a vaccine made from small protein pieces (peptides) designed to train the immune system to attack glioblastoma, a fast-growing brain cancer. The study includes 24 adults with newly diagnosed, untreated glioblastoma that has a specific genetic marker. …
Phase 1 • Sponsor: Mustafa Khasraw, MBChB, MD, FRCP, FRACP • Aim: Vaccine
Last updated Jun 27, 2026 12:26 UTC
-
Oral drug that targets two cancer drivers tested in first human study
Disease control By invitation onlyResearchers are testing an experimental oral drug called ND-003 in Chinese patients with advanced solid tumors that have worsened after standard treatment or have no standard options left. ND-003 blocks two proteins, NTRK and RET, that can drive cancer growth when altered. The ph…
Phase 1 • Sponsor: Shenzhen NewDEL Biotech, Co., Ltd • Aim: Disease control
Last updated Sep 21, 2026 19:00 UTC
-
Mitochondria-Targeting drug gamitrinib tested for first time in humans
Disease control PausedResearchers are running a first-in-human Phase 1 trial of gamitrinib, an experimental drug that targets mitochondria in cancer cells, in people with advanced solid tumors or lymphoma that have not responded to standard treatments. The main goal is to find the highest dose people …
Phase 1 • Sponsor: Fox Chase Cancer Center • Aim: Disease control
Last updated Sep 21, 2026 19:00 UTC
-
Targeted radiation zaps glioblastoma cells after surgery
Disease control OngoingThis early-phase trial tests a new treatment for glioblastoma, an aggressive brain cancer. After standard therapy (surgery, chemo, radiation), a radioactive antibody is injected into the brain cavity to target remaining tumor cells and delay recurrence. The study enrolls 15 adult…
Phase 1 • Sponsor: University Hospital Muenster • Aim: Disease control
Last updated Sep 21, 2026 19:00 UTC
-
New hope for kids with tough cancers: targeted drug attacks gene flaw
Disease control OngoingThis study tests a drug called ulixertinib in children and teens whose advanced cancers have a specific genetic change in the MAPK pathway. The goal is to see if the drug can shrink or control the tumor. About 20 participants with various solid tumors, lymphomas, or related disor…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 21, 2026 19:00 UTC
-
New drug cocktail aims to shrink Hard-to-Treat cancers
Disease control OngoingThis study tests an experimental drug called AZD5305, a PARP inhibitor, either alone or combined with other cancer drugs in people with advanced solid tumors (like ovarian, breast, pancreatic, and lung cancers). The goal is to see if the treatment is safe and can shrink tumors. A…
Phase 1/2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 21, 2026 19:00 UTC
-
New antibody drug conjugate tested against advanced cancers
Disease control OngoingResearchers are running a first-in-human phase 1 study of TORL-4-500, an antibody drug conjugate, in adults with advanced solid tumors, including hepatocellular carcinoma. The study has two parts: one to find the highest safe dose and the recommended dose for later trials, and an…
Phase 1 • Sponsor: TORL Biotherapeutics, LLC • Aim: Disease control
Last updated Sep 21, 2026 19:00 UTC
-
Brain cancer vaccine trial combines custom peptides with electric fields
Disease control OngoingThis early-phase trial tests whether a personalized vaccine made from each patient's tumor mutations, combined with Tumor Treating Fields (a device that sends electric fields to the brain), is safe and feasible for people with newly diagnosed glioblastoma. The 13 participants rec…
Phase 1 • Sponsor: Adilia Hormigo • Aim: Disease control
Last updated Sep 21, 2026 19:00 UTC
-
New drug cocktail takes on glioblastoma in early trial
Disease control OngoingThis early-stage study tests whether adding an experimental drug called OKN-007 to standard chemoradiotherapy is safe and tolerable for people with newly diagnosed glioblastoma, a fast-growing brain cancer. About 27 participants will receive the combination after surgery. The mai…
Phase 1 • Sponsor: University of Oklahoma • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Immune cells take on tough tumors in early trial
Disease control OngoingThis early-stage trial tests a personalized cell therapy (TIL injection) for people with advanced solid tumors that have spread or come back. The treatment uses the patient's own immune cells, grown in a lab, to fight the cancer. The main goal is to check safety, and the study wi…
Phase 1 • Sponsor: Grit Biotechnology • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
Immunotherapy duo takes on resistant germ cell tumors
Disease control OngoingThis phase 2 trial tests two immunotherapy drugs, durvalumab and tremelimumab, in 30 adults with relapsed or refractory germ cell tumors. The goal is to see if the combination can shrink tumors or lower tumor markers. Participants must have measurable disease and have progressed …
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New cancer drug combo enters human testing
Disease control OngoingThis early-stage trial tests a new drug called denikitug, alone or with another drug (zimberelimab), in 416 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drugs shrink tumors…
Phase 1 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Brain cancer trial: one big dose or several small doses of radiation?
Disease control OngoingThis phase III trial tests whether giving several small doses of radiation (fractionated radiosurgery) after removing a brain tumor is better than a single large dose. About 242 patients with cancer that spread to the brain will be randomly assigned to one of the two radiation pl…
Phase 3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New drug combo shows promise for Hard-to-Treat brain cancer
Disease control OngoingThis early-phase study tests a combination of two drugs, acalabrutinib and durvalumab, in people with primary central nervous system (CNS) lymphoma—a rare and aggressive brain cancer. The study includes up to 25 patients whose cancer has returned after prior treatment or who cann…
Phase 1 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
Can a pill that starves tumors of oxygen help fight advanced cancer?
Disease control OngoingThis early-stage trial is testing an experimental drug called belzutifan in people with advanced solid tumors that have not responded to standard treatments. Belzutifan works by blocking a protein (HIF-2α) that tumors use to survive in low-oxygen conditions. The main goal is to f…
Phase 1 • Sponsor: Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New drug combo targets deadly brain cancer in early trial
Disease control OngoingThis early-phase study tests whether adding the drug ibrutinib to standard radiation and chemotherapy is safe for people with newly diagnosed glioblastoma, a fast-growing brain cancer. About 36 adults with specific tumor types (MGMT methylated or unmethylated) will receive differ…
Phase 1 • Sponsor: Case Comprehensive Cancer Center • Aim: Disease control
Last updated Sep 18, 2026 00:00 UTC
-
New drug targets genetic weakness in Hard-to-Treat cancers
Disease control OngoingThis study tests a drug called erdafitinib in people whose cancers have extra copies of the FGFR gene. The drug blocks a faulty protein that helps cancer grow. Researchers want to see if it can shrink tumors or stop them from getting worse. About 35 adults with advanced or hard-t…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Walk or cycle before cancer treatment: new study tests exercise boost
Disease control OngoingThis early-phase study tests whether 30 minutes of moderate exercise (like walking or cycling) right before standard immunotherapy can improve treatment for certain skin cancers (melanoma, squamous cell carcinoma, Merkel cell carcinoma). About 22 adults will exercise before each …
Early phase 1 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New drug cocktail shows promise in early cancer trial
Disease control OngoingThis phase 1 trial is testing the safety and best dose of a combination of three drugs—entinostat, nivolumab, and ipilimumab—in people with advanced solid tumors that have spread or cannot be removed. The goal is to see if this mix can help the immune system fight cancer more eff…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New cancer drug BNT314 enters first human safety trial
Disease control OngoingThis study is the first time BNT314 is being tested in humans. It aims to see if the drug is safe for people with advanced solid tumors that have not responded to other treatments. About 41 participants will receive different doses to find the highest dose that is still safe and …
Phase 1 • Sponsor: BioNTech SE • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Supercharged immune cells injected into brain to fight tumors
Disease control OngoingThis early-phase trial tests a new approach for people with HER2-positive brain tumors that have come back or not responded to standard treatment. Researchers take the patient's own T cells, attach a special antibody (anti-HER2) to them, and inject these 'CAR T cells' directly in…
Phase 1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New drug cocktail targets rare eye cancer
Disease control OngoingThis phase II trial tests two drugs—olaparib and pembrolizumab—together in 12 people with advanced uveal melanoma, a rare eye cancer that has spread. The goal is to see if the combination can shrink tumors or slow the disease. The study is active but no longer recruiting, and res…
Phase 2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Targeted pill takes aim at rare cancer mutations
Disease control OngoingThis phase 2 trial is testing the drug osimertinib in 19 patients with advanced cancers (like lymphoma or solid tumors) that have specific EGFR mutations. Osimertinib is a pill that blocks the faulty EGFR protein, which can help stop tumor growth. The study aims to see if the dru…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New drug combo targets Hard-to-Treat cancers in early trial
Disease control OngoingThis early-phase trial tested the safety and best dose of two drugs—riluzole and sorafenib—given together to people with advanced solid tumors or melanoma that had spread and stopped responding to standard treatments. The goal was to find the highest safe dose and see if the comb…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Experimental vaccine takes on deadly childhood brain tumors
Disease control OngoingThis phase 1 trial tests a peptide vaccine designed to target a specific mutation (H3K27M) found in certain aggressive brain tumors called diffuse midline gliomas. Fifteen newly diagnosed patients receive the vaccine along with the immunotherapy drug atezolizumab after standard r…
Phase 1 • Sponsor: German Cancer Research Center • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
New drug targets Sugar-Coated proteins on cancer cells
Disease control OngoingResearchers are testing an experimental oral drug called PhOx430 in people with advanced solid tumors, including glioblastoma and triple-negative breast cancer. The trial has two parts: first, they give increasing doses to small groups to find a safe dose and watch for side effec…
Phase 1 • Sponsor: Phost'In Therapeutics • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Two-Drug combo aims to outsmart recurrent brain tumors
Disease control OngoingThis trial compares a combination of two drugs (cediranib and olaparib) against a single drug (bevacizumab) in people whose glioblastoma has returned after prior treatment. The goal is to see if the combination can delay tumor growth better than the standard approach. Participant…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 17, 2026 00:00 UTC
-
Can spreading out radiation beat a single dose for brain tumors?
Disease control OngoingThis Phase III trial tests whether giving radiation in three smaller doses (FSRS) works better than a single large dose (SRS) for cancer that has spread to the brain. About 269 adults with lung, breast, melanoma, kidney, or gastrointestinal cancers will be randomly assigned to on…
Phase 3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New antibody aims to preserve immune checkpoint while fighting cancer
Disease control OngoingResearchers are testing an experimental antibody called ONC-392 in people with advanced solid tumors, including non-small cell lung cancer and melanoma. The trial gives ONC-392 alone or with pembrolizumab, an approved immunotherapy, to see what doses are safe and how the body pro…
Phase 1/2 • Sponsor: OncoC4, Inc. • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Nasal spray shows promise against deadly brain cancer
Disease control OngoingThis study tests a nasal spray drug called NEO100 (perillyl alcohol) in people with aggressive brain tumors (grade III or IV gliomas) that have come back or worsened. The trial has two phases: first to find the safest dose, then to see if it helps patients live longer. About 49 p…
Phase 1/2 • Sponsor: Neonc Technologies, Inc. • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New drug combo shows promise in battling recurrent ovarian cancer
Disease control OngoingThis study tested a combination of two drugs, veliparib and topotecan, in 88 patients with solid tumors or ovarian cancer that returned after initial treatment. The goal was to find the safest dose and see how well the drugs shrink tumors. While the treatment aims to control the …
Phase 1/2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Experimental drug combo targets brain cancer metabolism
Disease control OngoingThis early-phase trial tests a new drug called telaglenastat combined with standard radiation and chemotherapy for people with a specific type of brain tumor (IDH-mutated astrocytoma). The goal is to find the safest dose and see if the combination works better than standard treat…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New trial tests smarter radiation to protect memory in lung cancer patients
Disease control OngoingThis phase III trial is testing whether a precise, high-dose radiation technique called stereotactic radiosurgery (SRS) is better at preserving memory and thinking than the current standard of whole brain radiation that avoids the hippocampus (the brain's memory center) plus a dr…
Phase 3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
Precision radiation may spare brain function in lung cancer patients
Disease control OngoingThis study looks at whether using focused radiation (stereotactic radiosurgery) only on the brain tumors, instead of the whole brain, can help preserve thinking and memory in people with small cell lung cancer that has spread to the brain. About 55 participants will receive this …
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New hope for rare cancers: drug duo shows promise
Disease control OngoingThis phase II trial tests whether combining two drugs, atezolizumab and bevacizumab, can shrink rare solid tumors like appendix cancer, anal cancer, and mesothelioma. About 133 participants with various rare cancers will receive the drugs intravenously. The goal is to see if the …
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New drug cocktail shows promise for tough childhood brain cancers
Disease control OngoingThis trial is testing whether adding hydroxychloroquine to two targeted cancer drugs (dabrafenib and trametinib) can help children and young adults with certain brain tumors that have come back or not responded to treatment. The study includes patients with specific genetic chang…
Phase 1/2 • Sponsor: Pediatric Brain Tumor Consortium • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New Dual-Action antibody takes on Hard-to-Treat cancers
Disease control OngoingThis early-phase study tests a new drug, RO7247669, that targets two immune system checkpoints (PD-1 and LAG-3) to help the body fight cancer. About 170 adults with advanced solid tumors (including melanoma, lung cancer, and esophageal cancer) who have run out of standard options…
Phase 1/2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New combo therapy aims to fight aggressive brain tumors in kids
Disease control PausedThis study tests a combination of a vaccine targeting the CMV virus (PEP-CMV) and an immunotherapy drug (nivolumab) in children and young adults with certain aggressive brain tumors, including diffuse midline glioma and medulloblastoma. The goal is to see if this approach is safe…
Phase 1/2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New drug combo shows promise for Hard-to-Treat cancers
Disease control OngoingThis early-stage trial tested the safety and best dose of two drugs, ixabepilone and temsirolimus, given together to adults with advanced solid tumors that had spread or could not be removed. The goal was to find a dose that limits side effects while potentially killing more canc…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New immune drug shows promise in early trial for Hard-to-Treat cancers
Disease control OngoingThis study tests an experimental drug called TransCon IL-2 β/γ, which aims to boost the immune system to fight cancer. It is given alone or with other treatments like pembrolizumab (Keytruda) or chemotherapy. The trial includes 320 adults with advanced solid tumors that have not …
Phase 1/2 • Sponsor: Ascendis Pharma Oncology Division A/S • Aim: Disease control
Last updated Sep 13, 2026 00:00 UTC
-
New drug combo shows promise for tough cancers
Disease control OngoingThis early-phase trial tests a new drug called BAY 1895344 combined with standard chemotherapy (irinotecan or topotecan) in people with advanced solid tumors, especially small cell lung cancer, poorly differentiated neuroendocrine cancer, and pancreatic cancer. The goal is to fin…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New combo shows promise for rare adrenal cancers
Disease control OngoingThis study tests whether adding olaparib to the standard chemotherapy temozolomide helps control advanced pheochromocytoma or paraganglioma—rare neuroendocrine tumors that have spread or can't be removed surgically. About 46 adults with these cancers will be randomly assigned to …
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
New Immune-Boosting drug GEN1042 tested in japanese cancer patients
Disease control OngoingThis early-stage study tests a new drug called GEN1042, which aims to help the immune system fight cancer. It is being tested alone or with other cancer drugs in 42 Japanese adults with advanced solid tumors. The main goal is to check safety and find the right dose.
Phase 1 • Sponsor: Genmab • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Drug combo aims to starve and block cancer in early trial
Disease control OngoingThis early-phase trial tested two oral drugs, cediranib and selumetinib, in 19 people with advanced solid tumors (including melanoma) that had stopped responding to standard treatments. Cediranib works by cutting off blood supply to tumors, while selumetinib blocks a key growth s…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Brain tumor treatment showdown: should radiation come before or after surgery?
Disease control OngoingThis phase III trial tests whether giving focused radiation (stereotactic radiosurgery) before surgery is better than after surgery for people with 1 to 4 brain metastases. About 237 participants will be randomly assigned to one of the two sequences. The goal is to see which orde…
Phase 3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Radioactive drug lutathera takes on brain cancer in early trial
Disease control OngoingThis phase 1 trial tests a radioactive drug called Lutathera in people with glioblastoma, an aggressive brain cancer. The study includes two groups: newly diagnosed patients receiving Lutathera with standard radiation and chemotherapy, and patients with recurrent glioblastoma rec…
Phase 1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Personalized dosing of cancer drug pazopanib tested in early trial
Disease control OngoingThis phase I trial tests the drug pazopanib (Votrient) in 54 patients with advanced solid tumors that have spread or not responded to other treatments. Pazopanib works by blocking blood vessel growth that tumors need. Researchers aim to find the best dose that balances effectiven…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Could a malaria drug help fight cancer? early trial tests new combo
Disease control OngoingThis early-phase trial tests two drugs together—MK-2206 and hydroxychloroquine—in people with advanced solid tumors, melanoma, kidney, or prostate cancer. The goal is to find the safest dose and see how the combination affects cancer cell growth. About 62 participants will take b…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New drug combo targets Hard-to-Treat cancers in early trial
Disease control OngoingThis early-phase study tests a new drug called M9466, a PARP1 inhibitor, alone or combined with other drugs in 60 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and how the body processes the drug. Researchers …
Phase 1 • Sponsor: EMD Serono Research & Development Institute, Inc. • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Targeted drug shows promise for Hard-to-Treat brain and bile duct cancers
Disease control OngoingThis study tests a drug called olaparib in people with advanced cancers (like brain tumors, bile duct cancer, or other solid tumors) that have a specific gene change called IDH1 or IDH2 mutation. The drug works by blocking an enzyme that cancer cells need to grow. About 89 partic…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
Sound waves open brain barrier to attack deadly tumor
Disease control PausedThis early study tests a combination approach for recurrent glioblastoma, an aggressive brain cancer. The treatment uses focused ultrasound (NaviFUS) to temporarily open the blood-brain barrier, allowing the drug Avastin (bevacizumab) to reach the tumor more effectively. Ten adul…
Phase 1/2 • Sponsor: NaviFUS Corporation • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New pill combo aims to tame Hard-to-Treat cancers
Disease control OngoingThis early-phase study tests an experimental oral drug (E7727) combined with another oral drug (decitabine) in people with advanced solid tumors that have not responded to at least two prior treatments. The main goals are to find the safest dose and understand side effects. Up to…
Phase 1 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
Can a smartphone app help cancer patients kick the habit?
Disease control OngoingThis phase III trial tests whether a smartphone app called Quit2Heal can help cancer patients stop smoking better than the standard QuitGuide app. The study involves 427 adults with cancer who smoke and are interested in quitting. Participants use one of the two apps to get suppo…
Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New drug combo takes aim at brain lymphoma
Disease control OngoingThis phase 2 trial tests a combination of six drugs (TEDDI-R) in 48 adults with aggressive B-cell lymphoma that has spread to the central nervous system. The goal is to see if this mix can control the cancer better than current treatments. Participants receive the drugs in 21-day…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New cocktail aims to tame rare brain cancer
Disease control OngoingThis early-stage trial tests a combination of four drugs—lenalidomide, nivolumab, rituximab, and methotrexate—in people with primary CNS lymphoma, a rare cancer of the brain or spinal cord. The goal is to find the safest dose and see if adding lenalidomide and nivolumab to standa…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New hope for brain cancer? drug shows promise in early trial
Disease control OngoingThis study tests a drug called abemaciclib in people whose glioblastoma (a type of brain cancer) has come back. The drug is given before surgery to see how much reaches the tumor, and then to a separate group to see if it helps control the cancer for at least 6 months. The trial …
Phase 2 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New antibody takes on Hard-to-Treat cancers
Disease control OngoingThis early-stage trial tests a new drug called ICT01, a lab-made antibody, in 292 people with advanced cancers that have not responded to standard treatments. The drug is given alone or with another cancer drug (Keytruda). The main goals are to check safety and see if the drug ca…
Phase 1/2 • Sponsor: ImCheck Therapeutics, an Ipsen company • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Personalized cancer attack: new trial matches drugs to tumor genes
Disease control OngoingThis phase II trial tests whether giving cancer drugs based on a tumor's genetic makeup can help people with advanced solid tumors that cannot be removed by surgery or have spread. About 920 participants will receive a drug or drug combination tailored to their tumor's specific g…
Phase 2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
Could a common vitamin boost brain cancer treatment?
Disease control OngoingThis study tests whether adding niacin (vitamin B3) to standard treatment (radiation and chemotherapy) can help people with newly diagnosed glioblastoma, an aggressive brain cancer. The trial has two phases: first, finding a safe dose of niacin, and second, checking if it improve…
Phase 1/2 • Sponsor: AHS Cancer Control Alberta • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New drug combo shows promise for hard-to-treat HER2 cancers
Disease control OngoingThis study tests a drug called trastuzumab deruxtecan, alone or with other medicines, in people with advanced solid tumors that have a protein called HER2. The goal is to see if the drug can shrink or control these cancers. About 127 adults with tumors that cannot be removed by s…
Phase 2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New antibody combo shows promise for Hard-to-Treat cancers
Disease control OngoingThis study tests an experimental drug called LM-108, given alone or with another immunotherapy (toripalimab), in people with advanced solid tumors that have stopped responding to standard treatments. The trial has two phases: first, finding the safest dose, then expanding to see …
Phase 1/2 • Sponsor: LaNova Medicines Limited • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Can an immunotherapy drug outsmart a returning brain tumor?
Disease control OngoingThis phase 2 trial tests whether pembrolizumab, an immunotherapy drug, can help the immune system attack recurrent glioblastoma, an aggressive brain cancer that has come back. Researchers will give the drug to about 18 patients who need surgery for their tumor, and then study how…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New mRNA vaccine shows promise in fighting solid tumors
Disease control OngoingThis early-stage trial tests an experimental mRNA-based cancer vaccine (mRNA-4157) in 161 people with solid tumors. The vaccine is designed to train the immune system to attack cancer cells. Some participants receive the vaccine alone, while others get it with the immunotherapy d…
Phase 1 • Sponsor: ModernaTX, Inc. • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New cancer drug saruparib enters early human testing
Disease control OngoingThis early-stage trial is testing a new drug, saruparib, in 41 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, how it interacts with other common medications, and how well different pill versions wor…
Phase 1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Could cutting vitamin B6 boost cancer immunotherapy?
Disease control OngoingThis early-phase study tests whether a diet very low in vitamin B6 can make immunotherapy work better for people with solid tumors. About 20 adults aged 18-80 will follow this special diet for 6 weeks while continuing their regular immunotherapy. The main goal is to check if the …
Phase 1 • Sponsor: West China Hospital • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Can a new gemcitabine formulation outsmart advanced solid tumors?
Disease control OngoingThis phase 1 trial tests FF-10832, a liposomal version of the chemotherapy drug gemcitabine, in adults with advanced solid tumors, including biliary tract cancer, that have not responded to standard treatment or have no standard options. Researchers give the drug as an intravenou…
Phase 1 • Sponsor: Fujifilm Pharmaceuticals U.S.A., Inc. • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New liposome chemo shows promise in early cancer trial
Disease control OngoingThis early-stage trial tests FF-10850, a liposome-wrapped version of the chemotherapy drug topotecan, in 96 adults with advanced solid tumors like ovarian, cervical, and Merkel cell carcinoma. The main goals are to find the safest dose and understand side effects. Researchers hop…
Phase 1 • Sponsor: Fujifilm Pharmaceuticals U.S.A., Inc. • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
New drug combo targets tough cancers in early trial
Disease control OngoingThis early-phase study tests a new drug called MK-2870, either alone or with the immunotherapy pembrolizumab, in Japanese patients with advanced solid tumors or a type of lung cancer. The main goal is to check the safety and side effects of these treatments. About 30 people will …
Phase 1 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Can a cocktail of immune boosters shrink Hard-to-Treat tumors?
Disease control OngoingThis phase 1 trial tests whether combining several investigational immunotherapy drugs, with or without chemotherapy, can safely shrink advanced solid tumors. The study enrolls adults with cancers like non-small-cell lung cancer or triple-negative breast cancer that have progress…
Phase 1 • Sponsor: AbbVie • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Spinal injection of dual immunotherapy plus chemotherapy targets cancer spread to brain lining
Disease control OngoingThis phase I/II trial tests a combination of two drugs given directly into the spinal fluid for people with leptomeningeal metastasis, a condition where cancer spreads to the membranes covering the brain and spinal cord. The drugs are QL1706, a bispecific antibody that blocks two…
Phase 1/2 • Sponsor: Guangzhou Medical University • Aim: Disease control
Last updated Sep 04, 2026 00:00 UTC
-
Could a Pre-Surgery immune booster beat standard care for skin cancer?
Disease control PausedThis phase III trial compares adding the immunotherapy drug cemiplimab before surgery (with or without radiation) to standard surgery alone for people with stage III/IV squamous cell skin cancer that can be removed. The goal is to see if the combination improves event-free surviv…
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Precision drug shows promise for rare Gene-Driven cancers
Disease control OngoingThis study tests a drug called larotrectinib in 35 adults with advanced cancers (including lymphoma and solid tumors) that have a specific NTRK gene fusion. The drug blocks a faulty protein that tells cancer cells to grow, aiming to shrink tumors or stop them from spreading. Part…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New hope for rare tumors: tarlatamab trial opens
Disease control OngoingThis study tests the drug tarlatamab in people with advanced tumors that have a protein called DLL3. The goal is to see if the drug can shrink or control these tumors. About 29 adults with stage IV cancer will receive tarlatamab, and researchers will track how well it works and a…
Phase 2 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Two-Drug immune attack shows promise against returning brain tumors
Disease control PausedThis study tests whether a combination of two immunotherapy drugs (relatlimab and nivolumab) is safer and more effective than standard chemotherapy (lomustine) for people whose glioblastoma (a type of aggressive brain cancer) has returned after initial treatment. About 184 partic…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Promising drug targets rare childhood tumors in new trial
Disease control OngoingThis study tests a drug called alisertib in children and young adults (up to age 22) with rare, aggressive tumors called atypical teratoid rhabdoid tumors (AT/RT) in the brain or malignant rhabdoid tumors (MRT) elsewhere in the body. For patients whose cancer has come back or not…
Phase 2 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Cancer drug brigimadlin tested for Long-Term use in solid tumour patients
Disease control OngoingThis study looks at the long-term safety of brigimadlin, a cancer drug taken as tablets, in adults with solid tumours who have already received at least 4 cycles of it in a previous study. About 90 participants will take the drug once every 3 weeks, and doctors will monitor their…
Phase 2 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New drug duo aims to shrink hard-to-treat tumors
Disease control OngoingThis early-phase study tests a new experimental drug (BI 770371) alone or with another immunotherapy (ezabenlimab) in adults with advanced solid tumors who have run out of standard options. The main goal is to find a safe dose and check for side effects. Up to 36 participants wil…
Phase 1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Can a smart drug deliver a One-Two punch to advanced cancers?
Disease control PausedThis trial tests an experimental drug called CS5001, designed to seek out and destroy cancer cells that carry a specific marker (ROR1). It is being studied in people with advanced solid tumors or lymphomas that have progressed after standard treatments. The study will first find …
Phase 1 • Sponsor: CStone Pharmaceuticals • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New pill combo takes on Hard-to-Treat cancers
Disease control OngoingThis early-stage trial tests two experimental pills (PF-07799544 and PF-07799933) taken twice daily at home by adults with advanced solid tumors that have a specific gene change called BRAF V600. The study aims to find safe doses and see if the drugs can shrink tumors. About 124 …
Phase 1 • Sponsor: Pfizer • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
Can a Brain-Penetrating drug tackle recurrent glioblastoma?
Disease control OngoingThis phase 1 trial tests the safety and tolerability of an experimental drug called Fb-PMT in people with recurrent glioblastoma, an aggressive brain cancer. Fb-PMT targets multiple cancer signaling pathways and is designed to cross the blood-brain barrier to reach the tumor. Res…
Phase 1 • Sponsor: NanoPharmaceuticals LLC • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
New program helps cancer survivors fight heart disease with exercise
Disease control OngoingThis study tests a clinic program called ActivityChoice that helps cancer survivors become more physically active to lower their risk of heart disease. About 114 adult cancer survivors will be offered a choice of group in-person, group virtual, or self-monitored digital exercise …
Sponsor: University of Massachusetts, Worcester • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Immunotherapy shows promise for tough brain cancers
Disease control OngoingThis study tests whether two immunotherapy drugs, ipilimumab and nivolumab, can shrink or slow the growth of recurrent high-grade gliomas (brain tumors) that have a high number of genetic mutations. About 37 adults with recurrent WHO grade 4 glioma will receive these drugs. The g…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
New cancer drug AB598 enters first human tests
Disease control OngoingThis early-phase trial is testing an experimental drug called AB598, alone or with other cancer drugs, in 40 people with advanced solid tumors like lung, bladder, or breast cancer. The main goal is to check safety and find the right dose. It is not yet known if the drug helps shr…
Phase 1 • Sponsor: Arcus Biosciences, Inc. • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
New immunotherapy shows promise against multiple advanced cancers
Disease control OngoingThis study tests a new drug called Cetrelimab (JNJ-63723283) in 234 people with advanced solid tumors like lung, melanoma, bladder, and colorectal cancers. The drug works by blocking PD-1, a protein that stops the immune system from attacking cancer cells. The trial has two parts…
Phase 1/2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Sep 02, 2026 00:00 UTC
-
Laser and radiation combo takes on recurrent brain tumors
Disease control OngoingThis pilot study is testing a two-step treatment for people whose gliomas (a type of brain tumor) have come back after standard therapy. First, doctors use a laser guided by MRI to destroy as much tumor as possible. Then, they give a short course of focused radiation. The main go…
Sponsor: University of Maryland, Baltimore • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New hope for kids with rare cancers: drug targets tumor growth
Disease control OngoingThis phase 2 trial tests the drug cabozantinib in children and young adults with rare cancers like sarcomas, Wilms tumor, and others that have come back or not responded to treatment. Cabozantinib works by blocking enzymes that help tumors grow and form blood vessels. The study a…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Experimental drug duo targets Hard-to-Treat cancers
Disease control OngoingThis early-phase trial tests a new targeted drug called MLN0128 combined with bevacizumab (Avastin) in about 50 patients whose glioblastoma or other solid tumors have returned or not responded to standard treatment. The main goal is to find the safest dose and see how the body ha…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Cancer drug safety tracked in ongoing rollover trial
Disease control By invitation onlyThis study monitors long-term safety in 120 cancer patients who are already benefiting from treatments like JNJ-75348780, safimaltib, or ibrutinib in earlier trials. Participants have blood cancers, solid tumors, or prostate cancer. The goal is to track serious side effects over …
Phase 1 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New combo therapy aims to extend life in advanced head and neck cancer
Disease control OngoingThis phase 3 trial tested whether adding bevacizumab to standard chemotherapy helps people with head and neck cancer that has returned or spread. About 403 adults took part. The main goal was to see if the combination improved overall survival compared to chemotherapy alone.
Phase 3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Can stronger radiation beat brain cancer? new trial aims to find out
Disease control OngoingThis phase 2 trial compares two types of higher-dose radiation (IMRT or proton beam) plus the chemotherapy drug temozolomide against standard radiation plus temozolomide in 606 people with newly diagnosed glioblastoma. The goal is to see if the higher-dose approaches improve over…
Phase 2 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
Experimental cocktail targets Hard-to-Treat brain cancer
Disease control OngoingThis early-phase trial tests a combination of the targeted drug ibrutinib with several chemotherapy drugs (TEDDI-R) in people with primary CNS lymphoma, a rare and aggressive brain cancer. The study aims to find the safest dose of ibrutinib when used in this cocktail and to see h…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New hope for recurrent brain cancer: drug combo aims to outsmart tumors
Disease control OngoingThis study tests a combination of two drugs (tocilizumab and atezolizumab) plus targeted radiation in people whose glioblastoma brain tumor has returned. The goal is to make the tumor more responsive to the body's immune system. About 59 adults will take part to find the best dos…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
Can engineered immune cells beat tough B-Cell cancers?
Disease control OngoingThis trial tests a type of engineered immune cell therapy called 19(T2)28z1xx CAR T cells in adults with B-cell cancers that have returned or not responded to treatment. The main goal is to find the highest dose that causes few or mild side effects. Researchers will also check wh…
Phase 1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
New liposomal drug shows promise for Hard-to-Treat cancers
Disease control OngoingThis early-stage study tests a new drug called E7389 liposomal formulation in people with advanced solid tumors that have not responded to standard treatments. The main goal is to find the safest dose and check for side effects. The study also looks at how the drug works in speci…
Phase 1 • Sponsor: Eisai Co., Ltd. • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
Oral chemotherapy candidate utidelone moves to human testing for advanced cancers
Disease control OngoingThis early-stage trial evaluates the safety, tolerability, and how well the body absorbs utidelone in capsule form for people with advanced solid tumors, including metastatic breast cancer. The study has three parts: finding the safest dose, comparing the capsule to the injected …
Phase 1/2 • Sponsor: Beijing Biostar Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
Kids' brain tumor drugs tested for Long-Term safety
Disease control OngoingThis study follows 165 children who previously took dabrafenib and/or trametinib for certain brain tumors. Researchers want to see if these drugs are safe over the long term and how they affect growth. The children continue their treatment and are monitored for side effects and d…
Phase 4 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
Could a transplant drug boost brain cancer treatment?
Disease control OngoingThis early-phase trial tests adding mycophenolate mofetil, a drug usually used to prevent organ rejection, to standard chemotherapy and radiation for glioblastoma. The goal is to find a safe dose and see if the combination can make tumor cells more sensitive to treatment. About 6…
Phase 1 • Sponsor: Northwestern University • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
New pill takes on tough cancers in first human test
Disease control OngoingThis early-stage trial tests an experimental oral drug called CID-078 in 220 adults with advanced solid tumors that have not responded to standard treatments. The study is split into two parts: first, finding a safe dose, and then checking if the drug shrinks tumors. It is a firs…
Phase 1 • Sponsor: Circle Pharma • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
Cancer drug regorafenib gets a second chance in small continuation study
Disease control OngoingThis study allows people with solid tumors who are already taking the cancer drug regorafenib in another Bayer study to keep taking it after that study ends. The goal is to see how safe and tolerable the continued treatment is. Only 13 participants are enrolled, and they take the…
Phase 2 • Sponsor: Bayer • Aim: Disease control
Last updated Aug 28, 2026 00:00 UTC
-
New drug combo targets Hard-to-Treat cancers with MTAP deletion
Disease control OngoingThis early-stage trial is testing a new oral drug called S095035, alone or combined with another drug (TNG462), in 60 adults with advanced solid tumors that have a specific genetic deletion (MTAP). These cancers have not responded to at least one prior treatment. The study aims t…
Phase 1/2 • Sponsor: Servier Bio-Innovation LLC • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
New drug dostarlimab shows promise in early trial for advanced cancers
Disease control OngoingThis early-stage trial is testing a drug called dostarlimab in 730 people with advanced solid tumors that have not responded to other treatments. Dostarlimab works by helping the immune system recognize and attack cancer cells. The study is checking for safe doses and any side ef…
Phase 1 • Sponsor: Tesaro, Inc. • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
New hope for recurrent glioblastoma? drug combo enters early trial
Disease control OngoingThis early-phase trial is testing a combination of two drugs—atezolizumab (an immunotherapy) and cabozantinib (a targeted therapy)—in patients whose glioblastoma has returned after standard treatment. The goal is to see if the combination is safe and can help control the cancer. …
Phase 1/2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
New drug targets rare gene fusions in multiple cancers
Disease control OngoingThis phase 2 study tests the drug entrectinib in over 500 people with advanced solid tumors that have specific gene changes (NTRK, ROS1, or ALK fusions). The goal is to see if the drug can shrink tumors and control the disease. Participants have various cancer types, including lu…
Phase 2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
Can a Dual-Action drug outsmart advanced cancers?
Disease control OngoingThis early-stage trial is testing an experimental drug called IBI363 in people with advanced solid tumors or lymphoma that have progressed despite standard treatment. IBI363 is designed to boost the immune system in two ways: by stimulating immune cells with an IL-2-like signal a…
Phase 1 • Sponsor: Innovent Biologics (Suzhou) Co. Ltd. • Aim: Disease control
Last updated Aug 27, 2026 00:00 UTC
-
New drug cocktail aims to fight returning brain tumors
Disease control OngoingThis phase 2 trial tests a combination of three drugs—pembrolizumab (immunotherapy), olaparib (a targeted therapy), and temozolomide (chemotherapy)—in people with recurrent glioblastoma, a type of brain tumor that has come back after initial treatment. The study will enroll 78 ad…
Phase 2 • Sponsor: L. Nicolas Gonzalez Castro, MD, PhD • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
Proton boost: new hope for tough brain tumors?
Disease control OngoingThis study tests a higher dose of a precise type of radiation called proton therapy for people with aggressive meningiomas (brain tumors). The goal is to find a safe dose that can better control the tumor after surgery. The study includes 21 participants with either grade II or g…
Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
Extended look at gotistobart: could Long-Term use improve survival in advanced cancers?
Disease control By invitation onlyThis extension trial follows patients with advanced solid tumors who are already receiving or have received gotistobart in earlier studies. The goal is to assess long-term safety and overall survival over an extended period. Participants must be 18 or older and have been part of …
Phase 3 • Sponsor: OncoC4, Inc. • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
Engineered immune cells take aim at Hard-to-Treat brain tumors
Disease control OngoingThis early-stage trial tests a new type of CAR T-cell therapy designed to target a protein called MMP2 found on glioblastoma cells. The treatment uses a scorpion toxin fragment (chlorotoxin) to help the immune cells find and attack the tumor. Nineteen patients with recurrent or p…
Phase 1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
New drug combo shows promise for Hard-to-Treat cancers
Disease control OngoingThis study tests an experimental drug called CTL-002, given alone or with an approved immunotherapy, in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to find a safe dose and see if the combination can shrink tumors or slow thei…
Phase 1/2 • Sponsor: CatalYm GmbH • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Can a targeted antibody take on glioblastoma?
Disease control OngoingThis phase 1 trial is testing whether amivantamab, an antibody drug given by IV, is safe and tolerable for people with high-grade malignant brain tumors like glioblastoma. The study enrolls about 12 patients with recurrent glioblastoma or certain molecular subtypes. Participants …
Phase 1 • Sponsor: Institute of Cancer Research, United Kingdom • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC
-
Engineered immune cells take on childhood cancers in first human trial
Disease control By invitation onlyThis early-stage trial is testing a new treatment called GPC2 CAR T cells for children with neuroblastoma or retinoblastoma that has come back or not responded to standard treatments. The therapy uses a patient's own immune cells, which are modified in a lab to better recognize a…
Phase 1 • Sponsor: Stephan Grupp MD PhD • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Can trained immune cells outsmart brain tumors?
Disease control OngoingThis Phase I trial tests whether infusing specially trained immune cells, called TAA-T, can safely target and attack high-risk brain tumors in children and adults. The cells are made from the patient's own blood and are designed to recognize multiple tumor-related proteins, poten…
Phase 1 • Sponsor: Catherine Bollard • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Can a new biologic boost standard brain cancer therapy?
Disease control OngoingThis trial is testing whether adding an experimental drug called XS005 to the standard chemotherapy regimen (Stupp) is safe and shows promise for people with glioblastoma, an aggressive brain tumor. The study involves 13 adults aged 18 to 70 who will receive XS005 infusions over …
Phase 1/2 • Sponsor: Dushu Lake Hospital Affiliated to Soochow University • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Radioactive drug takes on brain cancer in early trial
Disease control OngoingThis early-phase trial is testing a radioactive drug called 131I-TLX101, given alongside standard care, for people newly diagnosed with glioblastoma, an aggressive brain cancer. The study involves 12 participants and aims to find the safest dose and check for side effects. It is …
Phase 1 • Sponsor: Telix Pharmaceuticals (Innovations) Pty Limited • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Can a virus injected into brain tumors fight recurrence?
Disease control OngoingThis trial tests whether an experimental virus called C134 is safe when injected directly into the brain tumor in people with recurrent malignant glioma, including glioblastoma. Participants receive two doses of the virus during surgery to remove the tumor. The study focuses on s…
Phase 1 • Sponsor: James Markert, MD • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Can engineered immune cells tackle brain lymphoma?
Disease control OngoingThis trial tests whether a type of personalized cell therapy called CAR T-cell therapy (axi-cel) can safely treat lymphoma that has returned or not responded to treatment in the central nervous system (brain and spinal cord). The study includes people with primary CNS lymphoma or…
Phase 1 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Cancer drug pertuzumab tested for Long-Term use in extension trial
Disease control OngoingThis study gives continued access to the cancer drug pertuzumab (Perjeta) for people with solid tumors who were already benefiting from it in a previous Roche trial. About 154 participants will receive the drug every 3 weeks, alone or with other treatments, until their disease wo…
Phase 3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New hope for advanced breast cancer: drug shows promise against brain tumors
Disease control OngoingThis study tests the drug trastuzumab deruxtecan in about 500 people with advanced HER2-positive breast cancer, some of whom also have brain metastases. The goal is to see how well the drug shrinks tumors and how long it keeps the cancer from growing. Participants receive the dru…
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Cancer patients who respond to drug get continued access in new study
Disease control By invitation onlyThis study offers ongoing treatment with the cancer drug durvalumab to people who have already completed a previous study and are still benefiting from the drug, as decided by their doctor. The main goal is to monitor safety and side effects. About 214 participants will be enroll…
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Can engineered immune cells tackle brain lymphoma?
Disease control OngoingThis early-phase trial is testing a type of immunotherapy called CD19CAR T-cells in people aged 16 and older with relapsed or refractory primary CNS lymphoma, a rare cancer of the brain or spinal cord. The treatment involves collecting a patient's own immune cells, engineering th…
Phase 1 • Sponsor: University College, London • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Can a smart drug home in on Hard-to-Treat cancers?
Disease control OngoingThis trial is testing an experimental drug called XNW27011 in people with advanced solid tumors, such as pancreatic, lung, ovarian, colorectal, biliary tract, stomach, or gastroesophageal junction cancer, that have not responded to or are not eligible for standard treatments. XNW…
Phase 1/2 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Triple immunotherapy attack shows promise for tough skin cancer
Disease control OngoingThis study tests a combination of three immunotherapy drugs (INCMGA00012, INCAGN02385, and INCAGN02390) in 12 adults with advanced Merkel cell carcinoma that continued to grow after standard treatment. The drugs are given by IV to help the immune system fight the cancer. The main…
Phase 2 • Sponsor: University of Washington • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Oxygen therapy shows promise in brain cancer fight
Disease control OngoingThis study tests whether adding an experimental drug called NanO2 to standard radiation and chemotherapy can help people with newly diagnosed glioblastoma, an aggressive brain cancer. NanO2 is designed to deliver more oxygen to tumors, which may make radiation work better. About …
Phase 2 • Sponsor: NuvOx LLC • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Can a pill target Hard-to-Treat bile duct cancers? a new drug puts FGFR2 mutations to the test
Disease control OngoingThis early-stage trial is testing an experimental oral drug, TYRA-200, in people with advanced bile duct cancer (intrahepatic cholangiocarcinoma) and other solid tumors that have specific changes in the FGFR2 gene. The study aims to find a safe and effective dose and to see wheth…
Phase 1 • Sponsor: Tyra Biosciences, Inc • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
New eye injection could spare sight in melanoma patients
Disease control OngoingThis Phase 3 trial tests a new drug called belzupacap sarotalocan (AU-011) for people with small choroidal melanoma or suspicious spots in the eye. The drug is injected into the eye and activated by a laser to target cancer cells. The study compares it to a sham (fake) procedure …
Phase 3 • Sponsor: Aura Biosciences • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Triple-Drug cocktail targets Hard-to-Treat cancers
Disease control OngoingThis early-phase trial tests a combination of three drugs—copanlisib, olaparib, and durvalumab—in people with advanced solid tumors that have spread or can't be removed by surgery. The goal is to find the safest dose and see if the drugs work together to shrink tumors. Only patie…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
DNA-Guided prescribing may shield young cancer patients from harmful drug reactions
Disease control OngoingThis trial tests whether analyzing a child's DNA before prescribing supportive care drugs can lower the risk of serious side effects. Children with cancer or those receiving a bone marrow transplant are randomly assigned to get either standard care or prescribing guided by their …
Sponsor: Murdoch Childrens Research Institute • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Cancer drug spartalizumab gets extended safety check in ongoing patients
Disease control OngoingThis study follows patients with advanced solid tumors who are already benefiting from the cancer drug spartalizumab (PDR001). The goal is to continue monitoring safety and side effects while allowing patients to keep receiving the treatment. About 120 participants are enrolled f…
Phase 1 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
Cancer drug futibatinib gets a safety check in Long-Term rollover study
Disease control OngoingThis study is for people with advanced or metastatic cancer who have already been taking futibatinib in a previous study and are still benefiting from it. The goal is to keep giving them the drug (alone or with fulvestrant) and watch for any side effects over a longer period. Onl…
Phase 2/3 • Sponsor: Taiho Oncology, Inc. • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
Cancer patients get extended access to promising immunotherapy
Disease control OngoingThis study offers continued treatment with atezolizumab (Tecentriq) to about 1,000 cancer patients who were already benefiting from it in earlier Roche-sponsored trials. Participants may also receive other drugs like bevacizumab or alectinib. The main goal is to provide ongoing a…
Phase 3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Brain tumor drug vorasidenib tested in everyday practice
Disease control OngoingThis study looks at how well the drug vorasidenib works and how safe it is for people with a slow-growing type of brain tumor called grade 2 astrocytoma or oligodendroglioma that has an IDH1 or IDH2 mutation. The study includes people aged 12 and older in China who are treated in…
Sponsor: Servier (Tianjin) Pharmaceutical Co. LTD. • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
Personalized weight loss coaching could help cancer survivors shed pounds
Disease control OngoingThis study tests different levels of a telephone-based weight loss program for cancer survivors who are overweight or obese. All participants start with a core program including written materials, a smartphone app, and optional coaching. Those who lose at least 2% of their weight…
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Vitamin c and iron combo takes on brain cancer in early trial
Disease control OngoingThis early-phase trial tests whether adding high-dose vitamin C and an iron supplement (ferumoxytol) to standard radiation and chemotherapy can help adults with newly diagnosed glioblastoma, an aggressive brain tumor. The study includes 17 participants and focuses on finding a sa…
Phase 1 • Sponsor: Bryan Allen • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Could a lighter immunotherapy schedule keep advanced cancers in check?
Disease control OngoingThis trial is for people with advanced cancers who have already responded well to 6 months of standard immunotherapy. It compares continuing the same drugs at the usual frequency versus giving them every 3 months. The goal is to see if the reduced schedule can prevent cancer prog…
Phase 3 • Sponsor: UNICANCER • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New drug targets Hard-to-Treat cancers in japanese patients
Disease control OngoingThis study tests a drug called sacituzumab govitecan (Trodelvy) in Japanese patients with advanced solid tumors, including certain breast and bladder cancers. The trial has two phases: first, to find the safest dose, and second, to see how well the drug shrinks tumors. Participan…
Phase 1/2 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Triple threat: new combo aims to tackle breast cancer brain metastases
Disease control OngoingThis study tests a three-part approach for people with breast cancer that has spread to the brain. First, they receive focused radiation (stereotactic radiosurgery) along with a drug called olaparib, which may make cancer cells more sensitive to radiation. After that, they get an…
Phase 1/2 • Sponsor: Colette Shen • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
New drug shows promise against multiple Hard-to-Treat cancers
Disease control OngoingThis study tests a drug called trastuzumab deruxtecan (T-DXd) in people with various advanced cancers that have a protein called HER2. The goal is to see if the drug can shrink tumors and control the disease. About 477 participants with cancers like bladder, cervical, ovarian, an…
Phase 2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
New immunotherapy targets tough pancreatic cancers in early trial
Disease control OngoingThis early-phase trial tests an experimental immunotherapy called ELI-002 7P in people with pancreatic or other solid tumors that have specific KRAS or NRAS gene mutations. The treatment aims to train the immune system to attack cancer cells. About 158 participants will receive t…
Phase 1/2 • Sponsor: Elicio Therapeutics • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Cancer patients get continued access to lifesaving drug in new study
Disease control OngoingThis study offers continued treatment with the cancer drug osimertinib to patients who have already benefited from it in a previous trial. The goal is to keep providing the drug while monitoring safety and side effects. About 37 adults with cancer who are still doing well on the …
Phase 3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
Cancer patients get continued access to key therapy in extension study
Disease control OngoingThis study provides ongoing access to atezolizumab-based treatment for people with cancer who were already in a Roche-sponsored trial. It includes up to 49 participants who need to continue their therapy because the drug isn't available locally. The main goal is to keep treatment…
Phase 3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New surgical flap aims to restore swallowing and speech in obese tongue cancer patients
Disease control OngoingThis pilot study tests a new surgical technique called the anterolateral thigh myofascial fat composite flap (ALT-MF) for repairing tongue defects after cancer surgery in obese patients (BMI 30 or higher). Traditional flaps can be too bulky in obese patients, leading to problems …
Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New cancer combo aims to shrink Hard-to-Treat tumors
Disease control OngoingThis study tests a new drug called marlotamig (REGN7075) alone or with cemiplimab (Libtayo) and sometimes chemotherapy in people with advanced solid tumors. The goal is to find the safest dose and see if the combination can shrink tumors. About 933 participants are being recruite…
Phase 1/2 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Adaptive radiation aims to outsmart aggressive brain tumors
Disease control OngoingThis study tests whether a personalized, two-phase radiation therapy approach can better control glioblastoma, an aggressive brain cancer. The treatment adapts the radiation plan based on tumor changes during therapy, potentially targeting the tumor more precisely while sparing h…
Sponsor: Sunnybrook Health Sciences Centre • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Cancer drug safety tracked over years in ongoing study
Disease control OngoingThis study follows 205 people with solid tumors who are already taking the cancer drug avelumab. Researchers want to see how safe the drug is over the long term and how long patients live or stay cancer-free. Participants continue their current treatment or are monitored after fi…
Phase 3 • Sponsor: EMD Serono Research & Development Institute, Inc. • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New combo therapy takes on deadly brain cancer
Disease control OngoingThis trial tests a combination of donor immune cells (targeting a common virus) and the drug pembrolizumab (Keytruda) in 58 people with glioblastoma, an aggressive brain cancer. The goal is to see if this approach can shrink tumors and help patients live longer. The study has two…
Phase 1/2 • Sponsor: Queensland Institute of Medical Research • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Cancer-Killing virus injected directly into tumors shows promise in Mid-Stage trial
Disease control OngoingThis study tests a virus called AdAPT-001 that is injected directly into tumors to kill cancer cells. It is for adults with advanced solid tumors that have not responded to standard treatments. The trial will check if the virus is safe and whether it works better when combined wi…
Phase 2 • Sponsor: EpicentRx, Inc. • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New drug combo aims to outsmart resistant cancers
Disease control OngoingThis early-phase trial tests a new drug, ASTX660, combined with the immunotherapy pembrolizumab in people with advanced solid tumors, including cervical and triple-negative breast cancers. The goal is to see if the combination is safe and can boost the immune system to fight canc…
Phase 1 • Sponsor: Institute of Cancer Research, United Kingdom • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New hope: drug combo aims to stop brain tumors in breast cancer patients
Disease control OngoingThis study tests whether adding the drug tucatinib to standard therapy (trastuzumab/pertuzumab or T-DM1) can prevent new or worsening brain metastases in people with advanced HER2+ breast cancer. About 48 participants who have stable disease elsewhere but a new brain tumor will r…
Phase 2 • Sponsor: Carey Anders, M.D. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New hope for kids with tough cancers: entrectinib trial underway
Disease control OngoingThis study tests a drug called entrectinib in children with advanced solid tumors or brain tumors that have come back or haven't responded to other treatments. The trial has two parts: first finding the best dose, then seeing how well it works in children whose tumors have specif…
Phase 1/2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New antibody drug takes on advanced tumors in first human trial
Disease control OngoingThis early-phase trial tests an experimental drug called IPH5301, which targets a protein called CD73 on cancer cells. The study involves 27 people with advanced solid tumors, including breast, lung, and pancreatic cancers. In the first part, IPH5301 is given alone to find a safe…
Phase 1 • Sponsor: Institut Paoli-Calmettes • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Experimental vaccine aims to rally immune system against recurrent brain cancer
Disease control OngoingThis early-stage trial tests a vaccine called PEP-CMV in 30 children and young adults (ages 3–35) whose medulloblastoma or malignant glioma has come back. The vaccine is designed to train the immune system to attack tumor cells that carry a common virus protein (CMV). Participant…
Phase 1 • Sponsor: Daniel Landi • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Could a Drug-Radiation combo tame brain tumors?
Disease control PausedThis study tests whether adding the drug azeliragon to targeted radiation therapy can safely shrink brain tumors and keep them under control longer. It involves 46 adults with cancer that has spread to the brain. The goal is to improve tumor control without causing serious side e…
Phase 1/2 • Sponsor: Baptist Health South Florida • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Immunotherapy drug aims to stop deadly skin cancer's return in high-risk patients
Disease control OngoingThis phase 3 trial tests whether the immunotherapy drug avelumab can keep Merkel cell carcinoma from returning in patients whose cancer has spread to lymph nodes and who have already had surgery or radiation. About 100 adults will receive either avelumab or a placebo every two we…
Phase 3 • Sponsor: University of Washington • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug AZD9592 enters first human trials for tough cancers
Disease control OngoingThis early-stage trial tests an experimental drug called AZD9592, alone or with other cancer drugs, in about 167 adults with advanced solid tumors (including lung, head & neck, and colorectal cancers). The main goals are to check safety, find the right dose, and see if the drug s…
Phase 1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Cancer cell therapy trial for brain tumor withdrawn before starting
Disease control CancelledThis study planned to test a new treatment combining CYNK-001 (natural killer cells from donated cord blood) with interleukin-2 in adults whose glioblastoma had returned and could be surgically removed. The goal was to see if this combination was safe and could extend the time be…
Phase 1/2 • Sponsor: Celularity Incorporated • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Immune booster vaccine shows promise against deadly brain cancer
Disease control OngoingThis study tests whether adding a personalized dendritic cell vaccine to standard chemotherapy can help people with newly diagnosed glioblastoma live longer. Twenty patients who had surgery and chemoradiation will receive the vaccine alongside temozolomide. The goal is to see if …
Phase 1/2 • Sponsor: University Hospital, Antwerp • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Brain tumor trial combines radiation with targeted drugs and immunotherapy
Disease control OngoingThis study tests whether adding focused radiation (stereotactic radiosurgery) to a combination of targeted drugs (binimetinib and encorafenib) and an immunotherapy (pembrolizumab) can better control melanoma that has spread to the brain. It includes 10 adults with a specific gene…
Phase 2 • Sponsor: UNICANCER • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
When is the best time to zap brain tumors? new trial tests before, during, or after surgery
Disease control OngoingThis trial looks at the best time to give radiotherapy for brain metastases that can be surgically removed. It compares giving radiation before surgery, during surgery, or after surgery. The goal is to see which timing best prevents the tumor from coming back. About 90 adults wit…
Sponsor: University Hospital Heidelberg • Aim: Disease control
Last updated Jun 27, 2026 12:38 UTC
-
New combo therapy aims to boost immune attack on brain cancer
Disease control OngoingThis phase 2 trial tests whether adding a dendritic cell vaccine and an immune-boosting drug (varlilumab) to standard chemotherapy can help people with newly diagnosed glioblastoma live longer. About 43 participants will receive the vaccine plus temozolomide, with some also getti…
Phase 2 • Sponsor: Annick Desjardins, MD • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
Virus therapy takes on Hard-to-Treat cancers
Disease control OngoingThis early-stage trial tests a new drug called EM-I-2024, made from a modified enterovirus, in 24 adults with advanced solid tumors that cannot be surgically removed and have not responded to other treatments. The drug is given either intravenously or directly into the artery fee…
Phase 1 • Sponsor: National Medical Research Radiological Centre of the Ministry of Health of Russia • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New drug duo aims to outsmart stubborn cancers
Disease control OngoingThis early-phase study tests a combination of two drugs—guadecitabine and pembrolizumab—in about 60 people with advanced solid tumours (like lung cancer) that no longer respond to standard therapies. The main goal is to find the safest dose and check for side effects. Researchers…
Phase 1 • Sponsor: Royal Marsden NHS Foundation Trust • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Drug combo shows promise in early ovarian cancer trial
Disease control OngoingThis early-phase trial tests two oral cancer drugs, niraparib and neratinib, given together. The first part aims to find the safest dose in people with advanced solid tumors. The second part checks if that dose can keep platinum-resistant ovarian cancer from growing for at least …
Phase 1 • Sponsor: Virginia Commonwealth University • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New hope for breast cancer patients with brain tumors: targeted drug shows promise
Disease control OngoingThis study tests a drug called trastuzumab-deruxtecan (T-DXd) in 28 people with HER2-low breast cancer that has spread to the brain. The goal is to see if the drug can shrink brain tumors. Participants receive the drug intravenously, and doctors monitor tumor response using brain…
Phase 2 • Sponsor: MedSIR • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New drug cocktail shows promise for lung cancer patients with brain tumors
Disease control OngoingThis phase 2 trial is testing a combination of two immunotherapy drugs (nivolumab and ipilimumab) plus two cycles of chemotherapy as a first treatment for people with advanced lung cancer that has spread to the brain. The study aims to see if this approach can control the cancer …
Phase 2 • Sponsor: Fundación GECP • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New drug cocktail aims to tame deadly brain tumors
Disease control OngoingThis study tests whether adding the targeted drug pazopanib to standard chemotherapy (temozolomide) can safely control glioblastoma, an aggressive brain cancer. About 51 adults who had surgery and chemoradiation will receive the combination. The main goal is to find the best dose…
Phase 1/2 • Sponsor: Centre Antoine Lacassagne • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New hope for brain cancer: drug combo aims to extend survival
Disease control OngoingThis study tests whether adding the drug daratumumab to standard chemotherapy and radiation can help people with a newly diagnosed aggressive brain cancer called glioblastoma. About 16 participants will receive the combination treatment. The goal is to see if the new approach imp…
Phase 1/2 • Sponsor: West Virginia University • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New combo therapy aims to boost immunotherapy in Hard-to-Treat cancers
Disease control OngoingThis study tests whether adding an experimental drug called NP137 to standard immunotherapy (PD-1/PD-L1 blockers) can help shrink or control advanced solid tumors that are stable or resistant to treatment alone. About 57 adults with various advanced cancers will receive the combi…
Phase 2 • Sponsor: Centre Leon Berard • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug cocktail targets Hard-to-Treat brain cancer
Disease control OngoingThis phase 2 trial tests a combination of two drugs, tislelizumab and pemetrexed, in 28 adults with a rare type of brain lymphoma (primary DLBCL of the CNS) that has relapsed or not responded to standard treatment. The goal is to see if the combination can shrink tumors and impro…
Phase 2 • Sponsor: Seoul National University Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New radiation boost shows promise for elderly glioblastoma patients
Disease control OngoingThis phase 2 trial tests a higher radiation dose given over just 3 weeks for patients 65 and older with glioblastoma or grade 4 astrocytoma. Using a special MRI-guided machine (MR-Linac), doctors can adjust the radiation daily to target the tumor more precisely. The goal is to se…
Phase 2 • Sponsor: Sunnybrook Health Sciences Centre • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
Transplant patients with skin cancer get new hope from engineered virus
Disease control OngoingThis study tests a treatment called RP1, a modified herpes virus injected directly into skin tumors, in 69 people who have had an organ transplant and now have advanced skin cancer. The goal is to see if the virus can shrink tumors safely without harming the transplanted organ. P…
Phase 1/2 • Sponsor: Replimune, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New hope for brain cancer patients: drug combo targets aggressive tumors
Disease control OngoingThis study tests a combination of two drugs, L19TNF and lomustine, in 90 adults whose glioblastoma has returned or worsened. The goal is to find the safest and most effective dose to control the tumor and extend survival. Participants must have confirmed glioblastoma and be in ad…
Phase 2 • Sponsor: Philogen S.p.A. • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New antibody takes aim at Hard-to-Treat cancers
Disease control OngoingThis Phase 2 trial is testing a drug called PRL3-zumab in 60 people with advanced solid tumors that have not responded to standard treatments. PRL3-zumab is an antibody designed to attach to a protein called PRL3 found on cancer cells, potentially helping the immune system attack…
Phase 2 • Sponsor: Intra-IMMUSG Pte Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug combo tested for advanced cancers
Disease control OngoingThis early-phase trial is testing two different doses of vorinostat (a drug that blocks enzymes needed for cancer cell growth) combined with either carboplatin or paclitaxel (standard chemotherapy drugs) in 20 people with advanced solid tumors that have not responded to other tre…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
Can stronger, targeted radiation beat brain metastases without Whole-Brain side effects?
Disease control OngoingThis study tests whether giving higher doses of focused radiation (stereotactic radiosurgery) to brain tumors is safe and effective, without also radiating the whole brain. About 135 adults with certain types of cancer that have spread to the brain will receive escalating radiati…
Sponsor: University of Texas Southwestern Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New pill shows promise against Hard-to-Treat RET-Driven cancers
Disease control OngoingThis study tests an oral drug called selpercatinib in people with advanced solid tumors that have RET gene alterations, including certain lung, thyroid, and colon cancers. The goal is to find the best dose and see if the drug can shrink tumors. About 857 participants are enrolled…
Phase 1/2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Cancer patients get continued access to promising drug
Disease control OngoingThis study allows people with advanced cancers who are already benefiting from the drug ribociclib in a previous Novartis trial to keep receiving it. The goal is to provide continued access and monitor how long they stay on treatment and any side effects. Only 22 patients are enr…
Phase 2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Ultrasound device opens brain barrier to attack deadly tumors
Disease control OngoingThis trial tests an implantable ultrasound device that temporarily opens the blood-brain barrier, allowing chemotherapy to reach brain tumors. It includes 57 adults with recurrent glioblastoma who have already tried 1-2 treatments. The goal is to find a safe dose and see if this …
Phase 1/2 • Sponsor: Northwestern University • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
Immunotherapy drug aims to stop rare skin cancer's return
Disease control OngoingThis study tests whether the immunotherapy drug avelumab can help prevent Merkel cell carcinoma, a rare skin cancer, from returning after initial treatment. About 122 adults with stage I to III Merkel cell carcinoma will receive either avelumab or a placebo. The main goal is to s…
Phase 2 • Sponsor: Melanoma and Skin Cancer Trials Limited • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Aggressive chemo schedule put to the test in brain cancer trial
Disease control OngoingThis phase 3 trial tests whether giving the chemotherapy drug temozolomide earlier and for a longer time can help adults with glioblastoma live longer. About 486 participants will receive either the standard treatment or an intensified version that starts chemo within two weeks o…
Phase 3 • Sponsor: Centre Oscar Lambret • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
New combo therapy aims to halt merkel cell cancer spread
Disease control OngoingThis study tests whether adding radiation therapy (either external beam or a targeted radioactive drug called Lutathera) to the immunotherapy avelumab can help control metastatic Merkel cell carcinoma. About 19 adults with advanced disease will receive avelumab every two weeks fo…
Phase 1/2 • Sponsor: Melanoma and Skin Cancer Trials Limited • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
New radioactive drug targets childhood cancers that Won't quit
Disease control OngoingThis early-stage trial tests a radioactive drug called CLR 131 in 30 children and young adults with solid tumors, lymphoma, or brain tumors that have come back or not responded to standard treatments. The main goals are to find a safe dose and see if the drug can shrink tumors. P…
Phase 1 • Sponsor: Cellectar Biosciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Could less chemo be better? new trial aims to reduce treatment burden for brain lymphoma
Disease control OngoingThis Phase III trial tests whether a de-escalated (less intense) version of the standard MATRix chemotherapy regimen works as well for newly diagnosed primary CNS lymphoma. About 331 patients will receive either the standard four courses of MATRix or a reduced schedule with one c…
Phase 3 • Sponsor: Klinikum Stuttgart • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Targeted radiation shows promise for Hard-to-Treat blood cancers
Disease control OngoingThis study tests an experimental drug called iopofosine I 131 in people with certain blood cancers (like Waldenstrom macroglobulinemia, multiple myeloma, and lymphomas) that have come back or not responded to standard treatments. The drug delivers radiation directly to cancer cel…
Phase 2 • Sponsor: Cellectar Biosciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New hope for young brain tumor patients: drug combo targets IDH mutations
Disease control OngoingThis early-phase study tests a new drug (BGB-290) combined with chemotherapy (temozolomide) in teens and young adults with a type of brain tumor called glioma that has an IDH mutation. The goal is to find the safest dose and see how well the combination works for both newly diagn…
Phase 1 • Sponsor: University of California, San Francisco • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
RNA vaccine fights childhood cancers in new trial
Disease control OngoingThis study tests a new RNA-lipid particle vaccine for children and young adults (ages 3-25) with recurrent high-grade glioma or osteosarcoma that has spread to the lungs. The vaccine is made from the patient's own tumor material and aims to train the immune system to attack the c…
Phase 1/2 • Sponsor: University of Florida • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New drug combo targets Hard-to-Treat cancers in early trial
Disease control OngoingThis Phase I trial tests a combination of two oral drugs, defactinib and VS-6766, in people with advanced solid tumors such as non-small cell lung cancer, low-grade serous ovarian cancer, and pancreatic cancer. The study aims to find the safest dose and evaluate how well the drug…
Phase 1 • Sponsor: Institute of Cancer Research, United Kingdom • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Virus therapy takes on brain cancer in early trial
Disease control OngoingThis early-stage study tests a genetically engineered virus (rQNestin34.5v.2) that is injected directly into recurrent brain tumors to see if it is safe and what dose works best. About 62 adults with certain types of brain cancer that have come back or worsened are taking part. T…
Phase 1 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New hope for rare tumors: drug may slow cancer growth
Disease control OngoingThis study tests a drug called lanreotide in 10 people with advanced or metastatic paraganglioma or pheochromocytoma, rare tumors that release hormones. The goal is to see if lanreotide can slow tumor growth compared to before treatment. Participants receive injections every 4 we…
Phase 2 • Sponsor: Antonio Fojo • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Promising combo aims to tame relapsed childhood cancers
Disease control OngoingThis study tests a daily combination of sirolimus, celecoxib, and low-dose chemotherapy in 46 children whose solid or brain tumors have returned or not responded to standard treatment. The goal is to see if this approach can shrink tumors or stop them from growing. While not a cu…
Phase 2 • Sponsor: Emory University • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Experimental cancer combo aims to supercharge immune attack on tumors
Disease control OngoingThis early-phase trial tests an experimental drug called IMP321, which activates immune cells, in combination with other cancer treatments like chemotherapy or immunotherapy. The study includes 83 people with advanced solid tumors, including lung and bladder cancers. The main goa…
Phase 1 • Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Experimental cell combo takes on advanced cancers in early trial
Disease control OngoingThis early-stage trial is testing a new cell therapy called GK01 combined with a PD-1 immune checkpoint inhibitor in 15 people with advanced solid tumors (such as lung, stomach, or colorectal cancer). The main goal is to see if the combination is safe and tolerable, while also ch…
Phase 1 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Could a ketogenic diet help fight brain tumors?
Disease control OngoingThis pilot study tests whether an energy-restricted ketogenic diet (ERKD) can help control glioblastoma, an aggressive brain cancer. Sixteen adults with newly diagnosed glioblastoma will follow the diet while receiving standard radiation and chemotherapy. The goal is to see if th…
Sponsor: Michigan State University • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
New hope for brain cancer: triple therapy targets deadliest tumor
Disease control OngoingThis study tests whether adding the immunotherapy drug pembrolizumab to standard treatment (temozolomide chemotherapy and Tumor Treating Fields) can help people with newly diagnosed glioblastoma live longer without their cancer growing. About 40 adults with this aggressive brain …
Phase 2 • Sponsor: University of Florida • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Old drug, new hope? ibrutinib tackles tough brain cancer
Disease control OngoingThis study reviews medical records of 36 adults with relapsed or refractory primary central nervous system lymphoma (PCNSL) who were treated with ibrutinib alone or with R-CHOP chemo. The goal is to see how many patients respond to treatment. PCNSL is a rare and aggressive brain …
Sponsor: IRCCS San Raffaele • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Engineered immune cells take on deadly brain tumors
Disease control PausedThis early-stage trial tests a personalized cell therapy called IL13Rα2 CAR-T for people with recurrent grade 4 glioma, an aggressive brain cancer. The treatment involves collecting a patient's immune cells, engineering them to target a protein on tumor cells, and infusing them b…
Phase 1 • Sponsor: Yang Zhang • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New combo therapy before surgery shows promise for rare skin cancer
Disease control OngoingThis study tests whether giving a short course of chemotherapy plus immunotherapy before surgery can improve outcomes for people with Merkel cell carcinoma, a rare skin cancer. About 36 adults with operable tumors will receive one cycle of retifanlimab and platinum-etoposide befo…
Phase 2 • Sponsor: Gruppo Oncologico del Nord-Ovest • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New pill shows promise in Hard-to-Treat eye cancer
Disease control OngoingThis phase 2 trial tests a new drug called roginolisib against standard treatments in 85 adults with advanced uveal melanoma, a rare eye cancer. The study aims to see if roginolisib helps people live longer and improves their quality of life. Participants are randomly assigned to…
Phase 2 • Sponsor: iOnctura • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
New targeted drug aims to fight hard-to-treat bladder cancers
Disease control OngoingThis study tests a new drug called TYRA300 in people with advanced bladder cancer or other solid tumors that have a specific change in the FGFR3 gene. The goal is to find the best dose and see if the drug can shrink tumors. About 310 adults whose cancer has not responded to stand…
Phase 1/2 • Sponsor: Tyra Biosciences, Inc • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
New hope for kids with eye cancer: extra chemo may stop spread
Disease control OngoingThis study looks at whether giving chemotherapy (and sometimes radiation) after removing the eye can prevent retinoblastoma from coming back in children. About 195 children with advanced retinoblastoma in one eye took part. The goal is to see if this extra treatment reduces the c…
Phase 2 • Sponsor: Institut Curie • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
New oral drug shows promise for kids with rare RET-Driven cancers
Disease control OngoingThis study tests an oral drug called selpercatinib (LOXO-292) in children with advanced solid or brain tumors that have a specific RET gene change. The trial has two parts: first finding a safe dose, then measuring how many children's tumors shrink. About 36 children whose cancer…
Phase 1/2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
New drug shows promise for rare lung cancer subtype
Disease control OngoingThis phase 2 trial is testing a drug called taletrectinib in 217 people with advanced or metastatic ROS1-positive non-small cell lung cancer and other solid tumors. The main goal is to see how well the drug shrinks tumors and to check its safety. Participants take the drug by mou…
Phase 2 • Sponsor: Nuvation Bio Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
Experimental cell therapy targets aggressive brain tumors
Disease control OngoingThis early-phase study tests whether a new type of cell therapy, made from a patient's own immune cells that are genetically modified to resist chemotherapy, can be safely given alongside standard chemotherapy for newly diagnosed glioblastoma. About 22 adults with this aggressive…
Phase 1 • Sponsor: University of Alabama at Birmingham • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
Could a common antiviral help fight brain cancer?
Disease control OngoingThis phase 2 study tests whether adding the antiviral drug valganciclovir to standard treatment (radiation and chemotherapy) can help people with glioblastoma live longer. The idea is that many glioblastomas carry a virus called CMV, which may make the cancer more aggressive. Abo…
Phase 2 • Sponsor: Cecilia Soderberg-Naucler • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
Stem cells and immunotherapy join forces against childhood brain tumors
Disease control OngoingThis early-stage trial tests a new approach for children whose high-grade glioma has come back after standard treatments. It combines specially grown stem cells with an immunotherapy drug called nivolumab. The main goals are to see if the treatment is safe and possible to deliver…
Phase 1 • Sponsor: University of Florida • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
Immunotherapy duo takes on brain tumors in melanoma patients
Disease control OngoingThis study tests whether the immunotherapy drug nivolumab, alone or combined with ipilimumab, can shrink melanoma tumors that have spread to the brain. About 76 adults with stage IV melanoma and at least one brain metastasis will receive treatment. The main goal is to see how man…
Phase 2 • Sponsor: Melanoma Institute Australia • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New drug cocktail aims to outsmart advanced breast cancer
Disease control OngoingThis study is testing the safety and effectiveness of combining trastuzumab deruxtecan (T-DXd) with other cancer drugs for people with HER2-positive metastatic breast cancer. About 245 participants will receive different drug combinations to find the best doses and see if the tum…
Phase 1/2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
Engineered immune cells take on Hard-to-Treat cancers
Disease control OngoingThis early-stage study tests a new treatment called BOXR1030 for people with advanced solid tumors that have a specific marker (GPC3). The treatment uses specially designed immune cells given after chemotherapy to help fight the cancer. The main goals are to check safety and find…
Phase 1/2 • Sponsor: Sotio Biotech Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:02 UTC
-
Brain tumor patients may get a survival boost from targeted drug combo
Disease control OngoingThis study tests whether adding olaparib, a drug that blocks DNA repair in cancer cells, to standard chemoradiation can improve survival for people with high-grade gliomas that cannot be fully removed by surgery. The trial has two phases: first, finding the safest dose of olapari…
Phase 1/2 • Sponsor: Centre Francois Baclesse • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New chemo cocktails aim to save eyes in kids with retinoblastoma
Disease control OngoingThis phase 2 trial tests different chemotherapy regimens in 133 children with retinoblastoma, a rare eye cancer. The goal is to shrink tumors and avoid removing the eye or using radiation. Treatments include intravenous and intra-arterial chemotherapy, sometimes combined with las…
Phase 2 • Sponsor: Institut Curie • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
Immune cells and drugs injected directly into brain tumor in new trial
Disease control OngoingThis phase I/II trial tests a combination of immune cells (dendritic cells) and two immunotherapy drugs (ipilimumab and nivolumab) for people with recurrent glioblastoma, an aggressive brain cancer. The treatment is given directly into the tumor during surgery, followed by more d…
Phase 1/2 • Sponsor: Universitair Ziekenhuis Brussel • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
New drug combo shows promise in aggressive brain cancer trial
Disease control OngoingThis study tests whether adding the experimental drug LAM561 to standard radiation and chemotherapy can help people with newly diagnosed glioblastoma, a fast-growing brain tumor. About 144 adults aged 18 to 75 will receive either LAM561 or a placebo alongside their usual treatmen…
Phase 2/3 • Sponsor: Laminar Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Brain cancer breakthrough? trial adds radiation during surgery to fight glioblastoma
Disease control OngoingThis phase 3 trial tests whether giving a dose of radiation directly to the tumor site during surgery (intraoperative radiotherapy) can help people with a newly diagnosed aggressive brain cancer called glioblastoma live longer without their cancer growing. The study involves 314 …
Phase 3 • Sponsor: Universitätsmedizin Mannheim • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC
-
Engineered virus takes on deadly brain cancer
Disease control OngoingThis early-stage trial tests a single dose of M032, a genetically modified herpes simplex virus that produces IL-12, in 29 patients with recurrent or progressive brain tumors (glioblastoma, anaplastic astrocytoma, or gliosarcoma). The virus is infused directly into the tumor area…
Phase 1 • Sponsor: University of Alabama at Birmingham • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC
-
Brain cancer hope: new drug cocktail targets rare lymphoma
Disease control OngoingThis study tests whether adding lenalidomide or ibrutinib to standard chemotherapy (R-MPV) can improve outcomes for adults aged 18-65 with newly diagnosed primary central nervous system lymphoma. The trial has two parts: first, finding the safest dose, then randomly assigning pat…
Phase 1/2 • Sponsor: Institut Curie • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC
-
Experimental brain cancer vaccine made available to patients with no other options
Disease control Expanded access (ended)This program gives certain glioblastoma patients access to SurVaxM, a drug that helps the immune system fight brain cancer. It is for patients who cannot join other trials or who have already benefited from SurVaxM in a previous study. The treatment involves four doses given two …
Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Jun 26, 2026 18:27 UTC
-
New combo therapy aims to shrink eye tumors before radiation
Disease control By invitation onlyThis early-phase trial tests whether injecting the chemotherapy drug melphalan directly into the eye's blood vessels can shrink large uveal melanomas (eye cancers) enough to then treat them with radiation. Ten adults with tumors at least 8 mm thick will receive the chemo injectio…
Phase 1/2 • Sponsor: Hospital das Clínicas de Ribeirão Preto • Aim: Disease control
Last updated Jun 26, 2026 17:03 UTC
-
New combo attack on eye cancer that spreads to the liver
Disease control OngoingThis study tests a combination of two immunotherapy drugs (ipilimumab and nivolumab) plus a chemotherapy drug (melphalan) given directly to the liver through a special procedure. It includes 83 adults with advanced uveal melanoma that has spread mainly to the liver. The goal is t…
Phase 1/2 • Sponsor: Leiden University Medical Center • Aim: Disease control
Last updated Jun 26, 2026 15:09 UTC
-
Brain cancer boost: radioactive tile added to standard therapy in new trial
Disease control OngoingThis study tests whether adding a special radiation tile (GammaTile) during brain surgery, followed by standard chemotherapy and radiation, is safe and feasible for people with newly diagnosed glioblastoma. About 61 participants will receive the tile implant at the time of tumor …
Phase 4 • Sponsor: GT Medical Technologies, Inc. • Aim: Disease control
Last updated Jun 26, 2026 14:19 UTC
-
A new imaging agent aims to make solid tumors visible on PET scans
Diagnosis Expanded access (paused)This expanded access program lets people with advanced solid tumors receive an investigational imaging agent called MNPR-101-DFO*-89Zr before a PET/CT scan. The agent is designed to bind to uPAR, a protein found at higher levels in some tumors than in normal tissue. The goal is t…
Sponsor: Monopar Therapeutics • Aim: Diagnosis
Last updated Sep 06, 2026 00:00 UTC
-
AI that reads faces could spot hidden distress in cancer patients
Diagnosis By invitation onlyThis trial tests whether artificial intelligence can detect anxiety and depression in cancer patients by analyzing their facial expressions and subtle skin color changes from video. The AI uses computer vision to estimate heart rate and read emotional cues, aiming to flag patient…
Sponsor: Chinese PLA General Hospital • Aim: Diagnosis
Last updated Aug 16, 2026 00:00 UTC
-
Sound waves could make brain tumor diagnosis safer and smarter
Diagnosis OngoingThis trial explores whether focused ultrasound can enhance the release of tumor DNA into the blood and spinal fluid, potentially making liquid biopsies a more reliable way to diagnose brain tumors. Researchers will use MRI-guided focused ultrasound to partially ablate the tumor i…
Sponsor: University Health Network, Toronto • Aim: Diagnosis
Last updated Aug 15, 2026 00:00 UTC
-
Can a new PET tracer reveal hidden immune clues in tumors?
Diagnosis CancelledThis phase I trial tests an experimental imaging agent called 64Cu-DOTA-pembrolizumab, which is designed to attach to PD1, a protein on immune cells that often cluster around tumors. By injecting this agent and then performing a PET scan, researchers hope to see where these immun…
Phase 1 • Sponsor: City of Hope Medical Center • Aim: Diagnosis
Last updated Aug 14, 2026 00:00 UTC
-
New imaging agent could spot recurrent brain metastases more accurately
Diagnosis OngoingThis study tests a new imaging agent called RAD101, used with a PET scan, to see if it can better detect brain metastases that have come back after treatment. About 30 adults with certain cancers (like lung, breast, or melanoma) and suspected recurrent brain tumors will receive o…
Phase 2 • Sponsor: Radiopharm Theranostics, Ltd • Aim: Diagnosis
Last updated Aug 14, 2026 00:00 UTC
-
Can a new PET tracer spot tumors more clearly?
Diagnosis CancelledThis trial tests whether an experimental imaging agent, 18F-LNC1007, can improve the detection, staging, and recurrence monitoring of tumors compared to the standard 18F-FDG PET/CT scan. Adults with suspected or confirmed tumors will receive both types of scans within a week, and…
Sponsor: Jinling Hospital, China • Aim: Diagnosis
Last updated Aug 12, 2026 00:00 UTC
-
Finger-Prick test could replace needles for cancer blood monitoring
Diagnosis PausedThis study tests a new device that measures blood counts from a tiny finger-prick sample in cancer patients. Researchers will compare these results to standard lab tests from regular blood draws. The goal is to see if the device is accurate enough to eventually allow patients to …
Sponsor: Entia Ltd • Aim: Diagnosis
Last updated Jul 31, 2026 00:00 UTC
-
New MRI technique could end guesswork in brain tumor Follow-Up
Diagnosis OngoingThis study tests whether a special type of MRI scan can tell the difference between actual tumor growth and harmless treatment-related changes in people who have had surgery for a type of brain cancer called glioma. After treatment, it's often hard to know if a new spot on a scan…
Sponsor: Lanzhou University Second Hospital • Aim: Diagnosis
Last updated Jul 09, 2026 00:00 UTC
-
Could a routine blood test spot many cancers early?
Diagnosis OngoingThis study aims to create a screening tool that uses common blood test results to detect various cancers early. Researchers will analyze data from 10 million cancer patients and healthy individuals, using machine learning to find patterns. The goal is a low-cost, non-invasive tes…
Sponsor: Zhejiang Cancer Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 12:24 UTC
-
Hidden heart risk in cancer patients: simple ECG screening could save lives
Diagnosis OngoingThis study tests whether a simple 30-second ECG using a handheld device can find undiagnosed atrial fibrillation (an irregular heartbeat) in people aged 65 and older with cancer. About 500 participants will be randomly assigned to either get the quick screening or usual care. The…
Sponsor: University of Oklahoma • Aim: Diagnosis
Last updated Jun 27, 2026 12:04 UTC
-
New liquid biopsy could spot hidden brain lymphoma
Diagnosis OngoingThis study looks at whether a liquid biopsy (a simple test that checks for cancer DNA in spinal fluid) can better detect and monitor brain involvement in people with high-risk B-cell non-Hodgkin lymphoma. Researchers will compare this new method to standard tests in 64 newly diag…
Sponsor: Swiss Cancer Institute • Aim: Diagnosis
Last updated Jun 27, 2026 12:02 UTC
-
Simple blood test could transform cancer monitoring
Diagnosis OngoingThis study looks at whether liquid biopsies—simple blood tests that detect tumor DNA—can be used during regular doctor visits for people with advanced solid tumors. Researchers will collect blood samples from 159 patients and measure ctDNA levels to see how often the test finds t…
Sponsor: University Hospital, Basel, Switzerland • Aim: Diagnosis
Last updated Jun 27, 2026 11:00 UTC
-
New PET tracer could spot hidden cancers
Diagnosis OngoingThis early study tests a new radioactive tracer called 68Ga-FAPI-46, which targets a protein (FAP) found around many tumors. About 26 people with various cancers will get a PET/CT scan using this tracer to see where it goes in the body. The goal is to learn if this tracer can hel…
Phase 1 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Diagnosis
Last updated Jun 27, 2026 09:02 UTC
-
AI takes on cancer diagnosis: can a computer match expert pathologists?
Diagnosis By invitation onlyThis study compares a new AI system, called COSMO, against 30 board-certified pathologists to see who can more accurately diagnose brain, lung, and kidney cancers. Both the AI and the pathologists will review the same 300 de-identified tissue images. The goal is to see if AI can …
Sponsor: Harvard Medical School (HMS and HSDM) • Aim: Diagnosis
Last updated Jun 27, 2026 08:07 UTC
-
New ultrasound technique could spot eye tumors without a biopsy
Diagnosis OngoingThis study tests a special ultrasound technique called Superb Microvascular Imaging (SMI) to see blood flow inside eye tumors. The goal is to help doctors tell benign from malignant tumors more accurately, especially when standard tests are unclear. Twenty-two adults with untreat…
Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Diagnosis
Last updated Jun 27, 2026 08:01 UTC
-
Can more phone calls after cancer surgery keep patients out of the hospital?
Prevention OngoingResearchers are testing whether a more intensive follow-up plan after major cancer surgery can reduce emergency room visits, hospital readmissions, and deaths within 30 days. Patients in the intervention group receive scheduled nurse video visits, check-ins with a medical provide…
Phase 3 • Sponsor: Fox Chase Cancer Center • Aim: Prevention
Last updated Sep 21, 2026 19:00 UTC
-
Can a smaller dose of a white blood cell booster protect cancer patients just as well?
Prevention By invitation onlyResearchers are studying whether a lower 3mg dose of pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF) can prevent febrile neutropenia, a serious drop in infection-fighting white blood cells, in cancer patients after chemotherapy. The standard 6mg do…
Sponsor: Zhejiang Provincial People's Hospital • Aim: Prevention
Last updated Sep 20, 2026 00:00 UTC
-
Heart shield: diabetes drug may prevent Chemo-Induced cardiac damage
Prevention OngoingThis study tests whether empagliflozin, a drug used for diabetes, can prevent heart damage in cancer patients receiving strong chemotherapy (anthracyclines). About 220 adults with cancer but no prior heart failure will take either the drug or a placebo daily for 12 months. The go…
Phase 3 • Sponsor: Maria Sklodowska-Curie National Research Institute of Oncology • Aim: Prevention
Last updated Jun 27, 2026 14:00 UTC
-
Can a single day of brain radiation match five days?
Symptom relief OngoingResearchers are testing whether a one-day course of targeted radiation works as well as the standard five-day course for people whose cancer has spread to the brain. The trial enrolls about 100 adults with brain metastases and a poor prognosis. Everyone receives precise, image-gu…
Phase 2 • Sponsor: British Columbia Cancer Agency • Aim: Symptom relief
Last updated Sep 21, 2026 19:00 UTC
-
Hypnosis may calm cancer patients during radiation
Symptom relief OngoingThis study looks at whether medical hypnosis can help reduce anxiety in people with solid tumors who are getting radiation therapy. About 45 moderately to very anxious patients will either listen to relaxing music alone or combine it with hypnosis during their sessions. The goal …
Phase 2 • Sponsor: Institut Claudius Regaud • Aim: Symptom relief
Last updated Sep 21, 2026 19:00 UTC
-
Could two weeks of radiation be as good as six for this brain cancer?
Symptom relief OngoingThis study is for people with a rare and aggressive brain tumor called diffuse midline glioma. Instead of the usual six weeks of daily radiation, researchers are testing a shorter course of just two weeks. The goal is to see if the shorter treatment works just as well at controll…
Phase 2 • Sponsor: Mayo Clinic • Aim: Symptom relief
Last updated Sep 20, 2026 00:00 UTC
-
Can mindfulness ease cancer stress for latino families?
Symptom relief OngoingThis study is testing a culturally adapted mindfulness program for Latino cancer patients and their family caregivers. The goal is to see if the program is practical and helpful for reducing stress and anxiety. About 68 patient-caregiver pairs will take part, with some starting t…
Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Sep 19, 2026 00:00 UTC
-
Could a social media app help heal the emotional scars of cancer?
Symptom relief By invitation onlyThis trial tests whether a program designed to boost social connections can improve the social and emotional well-being of young adults who had cancer. Participants, aged 22-39 and diagnosed between 15-39, will receive a video and planning tools to encourage more in-person intera…
Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Symptom relief
Last updated Sep 18, 2026 00:00 UTC
-
New meditation program aims to ease cancer symptoms in black patients
Symptom relief OngoingThis study tests a supportive care program designed specifically for Black patients with advanced cancer. Participants will join weekly online sessions for four weeks, either practicing meditation or learning coping skills. The goal is to see if this culturally adapted program is…
Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Sep 18, 2026 00:00 UTC
-
New program aims to reduce shame from chronic illness
Symptom relief OngoingThis study tests a group counseling program called Healing HEARTS to help people with conditions like obesity, skin disease, cancer, HIV, diabetes, or chronic pain deal with internalized stigma. Participants will either join the counseling program or a peer support group. The goa…
Sponsor: University of Florida • Aim: Symptom relief
Last updated Sep 18, 2026 00:00 UTC
-
New radiation approach may spare thinking skills in brain cancer patients
Symptom relief OngoingThis study compares two radiation treatments for people whose non-melanoma cancer has spread to the brain with 4 to 15 tumors. One method, stereotactic radiosurgery, delivers a high dose only to the tumors, while the other treats the whole brain. The goal is to see which better c…
Phase 3 • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Sep 18, 2026 00:00 UTC
-
Needle in the spine: new hope for cancer pain?
Symptom relief OngoingThis study tests a procedure called cordotomy, where a needle is guided into the spinal cord to block pain signals. It's for people with advanced cancer who have severe pain on one side of the body below the shoulder. The goal is to see if it reduces pain better than a fake proce…
Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Sep 18, 2026 00:00 UTC
-
Nurses bring therapy to homebound cancer patients
Symptom relief OngoingThis study trains home-care nurses to deliver a short, meaning-centered psychotherapy to cancer patients who are homebound. The goal is to see if this approach can reduce psychological distress and improve quality of life. The trial involves 81 participants and focuses on trainin…
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Symptom relief
Last updated Sep 17, 2026 00:00 UTC
-
Spine radiation showdown: one big blast or three small doses?
Symptom relief OngoingThis study tests whether a single large dose of spine radiosurgery works better than three smaller doses for people whose spinal tumors have come back after previous radiation. About 80 adults with solid tumors that spread to the spine will be randomly assigned to one of the two …
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Sep 16, 2026 00:00 UTC
-
Can a common antipsychotic combo calm delirium in dying cancer patients?
Symptom relief OngoingThis study tests whether giving haloperidol alone or with chlorpromazine can safely calm severe agitation and confusion (delirium) in 70 advanced cancer patients in a palliative care unit. The main goal is to see if the drugs improve sedation scores within 24 hours. It is a phase…
Phase 2/3 • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Sep 16, 2026 00:00 UTC
-
Can a virtual stress program help working spouses care for cancer patients without burning out?
Symptom relief OngoingResearchers are testing a virtual stress-management program for people who care for a spouse or partner with a solid tumor cancer while also holding a job. The program teaches skills such as paced respiration, relaxation, and coping with work and caregiving demands across eight s…
Sponsor: University of Colorado, Denver • Aim: Symptom relief
Last updated Sep 13, 2026 00:00 UTC
-
Marijuana vs. opioids: which do cancer patients prefer for pain?
Symptom relief OngoingThis study looks at how cancer patients feel about using marijuana products (THC or CBD) compared to opioids for pain relief. Researchers will survey 200 adults with cancer-related pain who are already taking strong opioids. The goal is to understand patient preferences and perce…
Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Sep 13, 2026 00:00 UTC
-
Can a text message help depressed cancer survivors get the care they need?
Symptom relief OngoingDepression is common among cancer survivors, but many don't get help. This pilot study tests a text-based referral platform that sends tailored messages and a video to encourage survivors to take up a mental health referral. The study will enroll 60 cancer survivors with depressi…
Sponsor: Medical University of South Carolina • Aim: Symptom relief
Last updated Sep 11, 2026 00:00 UTC
-
Can a Five-Session program help young cancer patients keep their friendships?
Symptom relief OngoingResearchers are testing a five-session program called PRISM-SN for people aged 12 to 25 who were recently diagnosed with cancer and are receiving chemotherapy or radiation. The program teaches skills for managing stress, setting goals, reframing negative thoughts, finding meaning…
Sponsor: Seattle Children's Hospital • Aim: Symptom relief
Last updated Sep 11, 2026 00:00 UTC
-
Poetry therapy aims to bring purpose to LGBTQ+ cancer patients at end of life
Symptom relief OngoingThis study tests a type of talk therapy called dignity therapy, adapted for sexual and gender minority (LGBTQ+) cancer patients. A trained researcher will interview participants about their lives and create a poem or legacy document they can share with loved ones. The goal is to …
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Symptom relief
Last updated Sep 10, 2026 00:00 UTC
-
Money worries in cancer care: new program aims to keep patients on track
Symptom relief OngoingThis study tests a program called CostCOM that helps cancer patients with the high costs of treatment. Many patients skip or delay care because of money worries. The program provides financial advice and connects patients to resources. Researchers want to see if it helps patients…
Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Symptom relief
Last updated Sep 06, 2026 00:00 UTC
-
Which meditation works best for cancer survivors? a new study aims to find out
Symptom relief PausedThis pilot study explores how four different meditation practices—breathing only, focused attention only, mindfulness only, and a combination of all three—affect relaxation in cancer survivors. Many cancer patients experience stress and anxiety, and meditation may help reduce dis…
Sponsor: City of Hope Medical Center • Aim: Symptom relief
Last updated Sep 05, 2026 00:00 UTC
-
New digital coaching aims to ease cancer pain and cut opioid risks
Symptom relief OngoingThis study tests a program called ASCENT that helps cancer survivors manage pain using an educational guide and coaching from community health workers and pain care managers. The goal is to improve pain control and lower the risk of opioid misuse. About 660 adults with cancer-rel…
Sponsor: Mayo Clinic • Aim: Symptom relief
Last updated Sep 04, 2026 00:00 UTC
-
Sniffing lavender may ease biopsy pain and anxiety
Symptom relief PausedThis study tests whether inhaling lavender aromatherapy oil can reduce anxiety and pain for cancer patients undergoing a bone marrow biopsy. About 45 adults with cancer will be asked to use the oil during the procedure. The goal is to see if this simple, drug-free approach is som…
Sponsor: City of Hope Medical Center • Aim: Symptom relief
Last updated Sep 04, 2026 00:00 UTC
-
New coaching program aims to help young cancer survivors connect with friends
Symptom relief OngoingThis study tests a communication coaching program for adolescent and young adult cancer survivors (ages 18-35) who have finished treatment at least a year ago. Participants complete online sessions and AI coaching to improve how they talk with peers. The goal is to see if the pro…
Sponsor: Milton S. Hershey Medical Center • Aim: Symptom relief
Last updated Sep 03, 2026 00:00 UTC
-
Could neck adjustments relieve Cancer-Related fatigue?
Symptom relief CancelledThis trial tests whether six weeks of upper cervical chiropractic care can help adults who have finished cancer treatment but still struggle with chronic fatigue. The study focuses on whether such a trial is practical, looking at recruitment, adherence, and acceptability. Partici…
Sponsor: Life University • Aim: Symptom relief
Last updated Aug 29, 2026 00:00 UTC
-
New program aims to ease pain for kids battling cancer
Symptom relief OngoingThis study tests a program called TIPPI-R that teaches children with cancer and their families ways to manage pain and distress during treatment. About 100 children aged 0-18 will either receive the program or standard care. Researchers will compare how well they cope with pain a…
Sponsor: University of Louisville • Aim: Symptom relief
Last updated Aug 27, 2026 00:00 UTC
-
Talking therapy may offer a path away from opioids for cancer survivors
Symptom relief PausedThis pilot trial tests whether Acceptance and Commitment Therapy (ACT), a type of talking therapy, can help disease-free cancer survivors manage chronic pain and reduce long-term opioid use. Participants attend six weekly virtual sessions with a psychologist. The study focuses on…
Sponsor: Virginia Commonwealth University • Aim: Symptom relief
Last updated Aug 20, 2026 00:00 UTC
-
New online program aims to ease pain for cancer survivors
Symptom relief OngoingThis study tests whether an internet-based pain coping skills program can help cancer survivors manage ongoing pain. About 456 adults who have completed cancer treatment or are on maintenance therapy will take part. Participants will either get the online program plus enhanced us…
Sponsor: Wake Forest University Health Sciences • Aim: Symptom relief
Last updated Aug 13, 2026 00:00 UTC
-
A simple lotion duo may shield skin from Tumor-Treating fields
Symptom relief OngoingThis trial tests whether applying two topical lotions, clindamycin and triamcinolone, can prevent skin irritation caused by Tumor Treating Fields (TTFields) in people with glioblastoma. Participants will use the lotions at each array change, and researchers will track how many de…
Phase 2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Symptom relief
Last updated Aug 12, 2026 00:00 UTC
-
Virtual reality headsets may calm cancer patients before radiation
Symptom relief By invitation onlyThis trial tests whether a virtual reality (VR) educational video can reduce anxiety and improve satisfaction in adults starting their first course of external beam radiotherapy for cancer. Half of the 122 participants will watch a VR video through a headset before treatment, whi…
Sponsor: Oman Ministry of Health • Aim: Symptom relief
Last updated Aug 12, 2026 00:00 UTC
-
A digital bridge: could an online pathway ease depression in cancer care?
Symptom relief OngoingThis study tests an online pathway called iPath*D that guides cancer patients who report depression symptoms from screening to treatment options. The goal is to see if the tool is acceptable and easy to use for adults starting cancer treatment. Researchers will measure usability,…
Sponsor: Dartmouth-Hitchcock Medical Center • Aim: Symptom relief
Last updated Aug 09, 2026 00:00 UTC
-
Mind over body: new film series aims to boost wellbeing in young cancer survivors
Symptom relief OngoingThis study tests a digital program called EMBody for cancer survivors aged 16-25 who finished treatment up to seven years ago. The program uses short films and reflection activities to help them develop a healthier mindset about their body. Researchers want to see if it improves …
Sponsor: King's College London • Aim: Symptom relief
Last updated Aug 08, 2026 00:03 UTC
-
Community health workers step in to boost palliative care for black cancer patients
Symptom relief By invitation onlyThis study tests whether adding a trained community health worker (CHW) to standard care can improve quality of life and advance care planning for African American patients with advanced cancer. 160 patients will either receive standard care or standard care plus CHW support. The…
Sponsor: Wake Forest University Health Sciences • Aim: Symptom relief
Last updated Jul 25, 2026 00:00 UTC
-
Faith and mindfulness join forces to heal black cancer survivors
Symptom relief By invitation onlyThis trial tests a mindfulness program that blends stress-reduction techniques with Christian principles to improve well-being in Black adult cancer survivors. Participants take part in a silent mindfulness retreat, focus groups, interviews, and questionnaires. The study measures…
Sponsor: Mayo Clinic • Aim: Symptom relief
Last updated Jul 23, 2026 00:00 UTC
-
Can a smartphone app ease cancer Survivors' stress? new trial aims to find out
Symptom relief OngoingThis study tests whether a smartphone app that teaches mindfulness can help reduce stress in people who have finished cancer treatment. About 345 cancer survivors will be randomly assigned to use the app right away or wait three months. The goal is to see if the app makes a real …
Sponsor: Canadian Cancer Trials Group • Aim: Symptom relief
Last updated Jul 22, 2026 00:00 UTC
-
Testosterone gel trial aims to beat cancer fatigue in older men
Symptom relief OngoingThis study is testing whether a daily testosterone gel can reduce fatigue and improve sexual function in men aged 55 and older who have cancer and low testosterone. The trial involves 230 participants who will apply either the gel or a placebo for six months. Researchers will mea…
Phase 2 • Sponsor: Seattle Institute for Biomedical and Clinical Research • Aim: Symptom relief
Last updated Jul 08, 2026 00:00 UTC
-
Green tea extract tested to fight frailty in older cancer survivors
Symptom relief PausedThis phase 2 trial tests whether a daily dose of EGCG, a compound found in green tea, can reduce frailty and inflammation in people aged 65 and older who have survived cancer. About 118 participants will take either EGCG or a placebo for 12 weeks. The study is currently suspended…
Phase 2 • Sponsor: University of Rochester • Aim: Symptom relief
Last updated Jun 28, 2026 00:00 UTC
-
Money worries in cancer care: new study tests financial coaching to ease the burden
Symptom relief OngoingThis study tests whether a financial navigation and counseling program (CostCOM) can help newly diagnosed cancer patients who are struggling with costs or basic needs like food and housing. About 91 patients will either get the program, educational materials, or usual care. The g…
Sponsor: University of California, Irvine • Aim: Symptom relief
Last updated Jun 27, 2026 14:01 UTC
-
Cancer survivors find hope in Peer-Led Self-Management program
Symptom relief OngoingThis study tests a 7-session, peer-led self-management program for 234 cancer survivors who recently finished treatment with curative intent. The program aims to reduce anxiety and depression by teaching symptom management skills in a group setting. Participants are from central …
Sponsor: University of Aarhus • Aim: Symptom relief
Last updated Jun 27, 2026 13:08 UTC
-
New telehealth program aims to ease emotional burden of advanced cancer
Symptom relief By invitation onlyThis study is testing a 5-session telehealth program called CASA that helps advanced cancer patients and their caregivers cope with emotional and spiritual challenges. The program is designed for people with stage III or IV cancer and their caregivers. The goal is to see if it im…
Sponsor: Ponce Medical School Foundation, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 13:05 UTC
-
No more hospital trips? video nutrition counseling tested for cancer weight loss
Symptom relief OngoingThis study compares two ways of giving nutrition advice to cancer patients who have lost weight: video calls from home versus in-person hospital visits. Eighty adults with cancer and weight loss will receive personalized dietary counseling every two weeks for 12 weeks. The goal i…
Sponsor: King Edward Medical University • Aim: Symptom relief
Last updated Jun 27, 2026 13:04 UTC
-
Can exercising at home match gym sessions for cancer recovery?
Symptom relief OngoingThis study compares a 12-week digital home-based resistance exercise program to a supervised on-site program for cancer survivors who finished treatment up to 5 years ago. The main goal is to see which approach leads to better exercise adherence. Researchers will also measure eff…
Sponsor: Inland Norway University of Applied Sciences • Aim: Symptom relief
Last updated Jun 27, 2026 13:01 UTC
-
Holy Qur'an or music: which helps kids on chemo sleep better?
Symptom relief OngoingThis study compares listening to Holy Qur'an recitation versus calming music before bed in children aged 6 to 10 who are undergoing chemotherapy. Sleep problems are common in these children, and the goal is to find a safe, non-medication way to improve sleep quality. Ninety child…
Sponsor: Rawand Shafeeq Ali • Aim: Symptom relief
Last updated Jun 27, 2026 13:00 UTC
-
Lifting weights, lifting hope: exercise trial targets brain cancer decline
Symptom relief By invitation onlyThis study explores whether a supervised, circuit-based resistance training program can help glioblastoma patients maintain muscle mass and perform daily tasks more easily. Researchers will enroll 24 adults with glioblastoma who are currently on treatment. Participants will exerc…
Sponsor: Nova Scotia Health Authority • Aim: Symptom relief
Last updated Jun 27, 2026 13:00 UTC
-
Brain cancer radiation study pulled before it even started
Symptom relief CancelledThis trial planned to compare a second round of whole brain radiotherapy plus supportive care against supportive care alone for people with brain metastases that returned after initial treatment. It was designed for patients who could not have surgery or precise radiation. Howeve…
Sponsor: University Hospital Heidelberg • Aim: Symptom relief
Last updated Jun 27, 2026 12:29 UTC
-
Magic mushroom compound tested for Cancer-Related depression
Symptom relief OngoingThis study tests whether up to two doses of psilocybin (the active ingredient in magic mushrooms) can safely reduce depression in adults who have both cancer and major depressive disorder. About 56 participants will receive either psilocybin or a placebo in a first session, and t…
Phase 2 • Sponsor: Sunstone Medical • Aim: Symptom relief
Last updated Jun 27, 2026 12:29 UTC
-
Can a short talk therapy beat insomnia in cancer patients?
Symptom relief OngoingThis study tests whether a brief behavioral therapy (BBT-CI) or a healthy eating education program (HEAL) works better for reducing insomnia in cancer patients. About 400 adults with stage I-IV cancer who are currently receiving treatment and have sleep problems will take part. T…
Phase 3 • Sponsor: University of Rochester NCORP Research Base • Aim: Symptom relief
Last updated Jun 27, 2026 12:23 UTC
-
Exercise may soothe chemo nerve pain, trial hopes
Symptom relief OngoingThis study tests whether a structured exercise program can reduce chemotherapy-induced peripheral neuropathy (CIPN) — nerve damage causing pain, numbness, or tingling. About 133 cancer patients who received certain chemotherapies will either follow an exercise plan or receive sta…
Sponsor: University of Rochester NCORP Research Base • Aim: Symptom relief
Last updated Jun 27, 2026 12:23 UTC
-
Can spreading out brain radiation reduce side effects for immunotherapy patients?
Symptom relief OngoingThis study looks at two ways to give radiation to brain tumors in people who are also receiving immunotherapy for cancers like lung, breast, kidney, or melanoma. The standard approach gives one high dose of radiation, while the experimental approach gives smaller doses over sever…
Sponsor: Wake Forest University Health Sciences • Aim: Symptom relief
Last updated Jun 27, 2026 12:04 UTC
-
Smartphone app aims to ease suffering for advanced cancer patients
Symptom relief OngoingThis study tests whether a mobile app called SUPPORT+ can improve quality of life for adults with advanced cancer who are no longer receiving anticancer treatment. Participants use the app to report symptoms weekly, get self-care tips, and receive nurse follow-up if symptoms are …
Sponsor: The University of Hong Kong • Aim: Symptom relief
Last updated Jun 27, 2026 12:03 UTC
-
Spine adjustments tested as fatigue fix for cancer survivors
Symptom relief PausedThis pilot study explores whether chiropractic adjustments to the upper neck can reduce chronic fatigue in adults who have finished cancer treatment. About 40 cancer survivors who are currently cancer-free will receive either immediate or delayed chiropractic care for 6 to 12 wee…
Sponsor: Life University • Aim: Symptom relief
Last updated Jun 27, 2026 12:02 UTC
-
Cash for cancer care: $1,000 a month trial aims to ease financial burden
Symptom relief OngoingThis study gives 250 advanced cancer patients $1,000 each month for a year to see if it reduces financial stress and improves quality of life. Participants also complete surveys every three months. The goal is to learn whether extra income can help patients stick to treatments an…
Sponsor: Meredith Doherty, PhD, LCSW • Aim: Symptom relief
Last updated Jun 27, 2026 12:00 UTC
-
Could a simple referral to palliative care ease End-of-Life suffering for cancer patients?
Symptom relief OngoingThis study tests whether cancer patients who visit the emergency room for urgent problems benefit from being immediately referred to a palliative care team. The goal is to see if this reduces aggressive treatments and hospitalizations in the last month of life. The trial involves…
Sponsor: Centre Leon Berard • Aim: Symptom relief
Last updated Jun 27, 2026 09:06 UTC
-
Can acupuncture with electricity ease cancer brain fog and fatigue?
Symptom relief OngoingThis study tests whether electroacupuncture (a type of acupuncture with mild electrical pulses) can help cancer patients and survivors with clusters of symptoms like memory problems, fatigue, insomnia, anxiety, and depression. Seventy participants will receive either real electro…
Sponsor: University of California, Irvine • Aim: Symptom relief
Last updated Jun 27, 2026 08:13 UTC
-
Texts and trackers: new study aims to get young cancer survivors moving
Symptom relief OngoingThis study tests whether a mobile health program can help adolescents and young adults (ages 15-39) who finished cancer treatment become more physically active. Participants get a personalized activity plan, a fitness tracker, access to an online survivor community, and motivatio…
Sponsor: AHS Cancer Control Alberta • Aim: Symptom relief
Last updated Jun 27, 2026 08:09 UTC
-
Can a smartphone app boost quality of life for young cancer patients?
Symptom relief OngoingThis study tests whether a phone app called OnKO-Tips&Tricks can improve the quality of life for adolescents and young adults (ages 15-25) recently diagnosed with cancer. The app helps with daily check-ins, education, and connecting with a nurse coordinator. Researchers will comp…
Sponsor: University Hospital, Strasbourg, France • Aim: Symptom relief
Last updated Jun 27, 2026 08:08 UTC
-
Forest bathing tested as fatigue fix for cancer survivors
Symptom relief By invitation onlyThis study tests whether nature-based therapies can reduce fatigue and improve sleep, mood, and concentration in cancer survivors. 172 participants will be assigned to real forest bathing, a virtual reality forest experience, guided imagery, or a waitlist. Each session lasts 30 m…
Sponsor: Robert Bosch Gesellschaft für Medizinische Forschung mbH (RBMF) • Aim: Symptom relief
Last updated Jun 27, 2026 07:51 UTC
-
Can tumor profiling help kids beat cancer? new study aims to find out
Knowledge-focused OngoingThis study looks at whether testing the genes of a child's solid tumor can help doctors choose a more effective treatment. About 825 children and young adults with hard-to-treat solid tumors will have their tumors genetically profiled. The goal is to see if those who receive a tr…
Sponsor: Dana-Farber Cancer Institute • Aim: Knowledge-focused
Last updated Sep 21, 2026 19:00 UTC
-
10-Year NF1 study aims to unlock secrets of rare genetic disorder
Knowledge-focused OngoingThis natural history study follows 259 children, adolescents, and adults with Neurofibromatosis Type 1 (NF1) for up to 10 years. Researchers will track tumor growth, monitor quality of life, and perform genetic testing to better understand how the disease changes over time. The g…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
Radiation for 6+ brain tumors: how does it affect memory?
Knowledge-focused OngoingThis study looks at how precise radiation (stereotactic radiosurgery) affects memory and thinking in people with 6 or more brain tumors that have spread from other cancers. About 80 adults will take part to find the safest radiation dose and measure any decline in memory over 4 m…
Phase 1/2 • Sponsor: University of Texas Southwestern Medical Center • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
New study examines immunotherapy outcomes in american indian cancer patients
Knowledge-focused OngoingThis study reviews medical records of 72 American Indian patients treated with immunotherapy for cancers like lung cancer, melanoma, and kidney cancer. Researchers compare their outcomes—such as how long the cancer is controlled and side effects—to those of White patients. The go…
Sponsor: University of Oklahoma • Aim: Knowledge-focused
Last updated Sep 20, 2026 00:00 UTC
-
MD anderson study seeks to improve care for asian cancer patients
Knowledge-focused OngoingThis study aims to understand what helps or hinders a positive experience for Asian patients being treated for cancer at MD Anderson. Researchers will survey former patients and healthcare providers to identify key factors. The goal is to use these insights to improve care and su…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
Could a frailty score predict which older cancer patients survive intensive care?
Knowledge-focused OngoingOlder adults with cancer who need intensive care often face a higher risk of dying, and delays in moving them from the emergency department to the ICU may add to that risk. This study reviews the medical records of 150 patients aged 65 and older with solid or blood cancers who we…
Sponsor: Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital • Aim: Knowledge-focused
Last updated Sep 19, 2026 00:00 UTC
-
Massive NCI study tracks thousands of cancer patients receiving standard care
Knowledge-focused By invitation onlyThis study enrolls up to 10,000 cancer patients at the National Cancer Institute who are not on an active treatment research protocol. Participants receive standard medical care, including lab tests and scans, while researchers collect their health information to build a data rep…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Scientists track families to uncover Cancer's hidden causes
Knowledge-focused OngoingThis study looks at people and families who have a high risk of cancer to learn what genes and environmental factors might increase that risk. Over 5,000 participants are followed over time with questionnaires, medical records, and optional genetic testing. No treatment is given,…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
NIH launches massive sample collection to unlock disease secrets
Knowledge-focused By invitation onlyThis study collects blood, bone marrow, urine, and tissue samples from up to 6,000 people with solid tumors, blood cancers, or non-cancerous blood disorders, as well as from their healthy family members who are stem cell donors. The samples are stored and used in research to bett…
Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Knowledge-focused
Last updated Sep 18, 2026 00:00 UTC
-
Can a simple MRI spot early success in brain cancer treatment?
Knowledge-focused OngoingThis study tests whether a special MRI scan, called DSC-MRI, can measure blood flow changes in brain tumors to predict if the drug bevacizumab is working early in treatment. Researchers will scan 146 patients with recurrent glioblastoma before and two weeks after starting the dru…
Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Knowledge-focused
Last updated Sep 17, 2026 00:00 UTC
-
Community cancer Centers' testing practices under review
Knowledge-focused CancelledThis study aimed to evaluate how community cancer centers test for biomarkers in common solid cancers like breast, lung, and colorectal cancer. Researchers planned to survey pathology practices to see if they follow guidelines for key tests and how quickly results are reported. T…
Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Knowledge-focused
Last updated Sep 17, 2026 00:00 UTC
-
Apple watch could predict brain tumor complications
Knowledge-focused PausedThis study explores whether an Apple Watch can track walking, heart rate, breathing, and sleep in people with glioblastoma, a serious brain cancer. The goal is to see if the watch can detect symptom changes before they become serious, like seizures or blood clots. Twenty-five pat…
Sponsor: Case Comprehensive Cancer Center • Aim: Knowledge-focused
Last updated Sep 17, 2026 00:00 UTC
-
New MRI technique could predict memory loss after brain radiation
Knowledge-focused OngoingThis study follows 110 people with brain metastases who are receiving either focused or whole-brain radiation. Researchers use advanced MRI scans and memory tests before treatment and for two years after to see if the scans can predict thinking and memory problems. The goal is to…
Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Sep 13, 2026 00:00 UTC
-
Scientists watch brain tumors transform using advanced imaging
Knowledge-focused PausedThis study tracks a substance called 2-HG in the brains of people with a type of brain cancer (glioma) that has specific gene changes. By using special MRI scans over time, researchers hope to learn how and when these tumors become more aggressive. About 42 adults will have regul…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 10, 2026 00:00 UTC
-
Eye cancer survivors: does treatment choice impact Long-Term happiness?
Knowledge-focused By invitation onlyThis study looks at children and teens who survived retinoblastoma in one eye. Researchers want to see if those who had chemotherapy injected into the eye artery have a different quality of life than those who had the eye removed. Participants and their parents will fill out surv…
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Sep 10, 2026 00:00 UTC
-
Choice or fixed? study tests how to get better data from young cancer patients
Knowledge-focused OngoingThis study enrolls 400 adolescents and young adults (ages 18-39) recently diagnosed with various cancers. Participants are randomly assigned to either choose which health-related questions they answer or receive a fixed set of questions. The goal is to see if giving patients a ch…
Early phase 1 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Knowledge-focused
Last updated Sep 06, 2026 00:00 UTC
-
New study: diet and exercise may boost sleep and reduce stress in cancer survivors
Knowledge-focused OngoingThis study is testing a 24-week program that combines nutrition counseling, exercise, sleep tips, and stress management for cancer survivors who are overweight. Researchers want to see if the program is practical and helpful for improving sleep quality, reducing stress, and boost…
Sponsor: University of Colorado, Denver • Aim: Knowledge-focused
Last updated Sep 05, 2026 00:00 UTC
-
50,000 samples to unlock secrets of hereditary tumors
Knowledge-focused CancelledThis study will collect blood and tumor tissue from up to 50,000 adults with hereditary or genetic-linked cancers. Researchers will use these samples to create lab-grown tumor models, like mini-tumors, to study how these cancers work and test new treatments. The goal is to better…
Sponsor: University of California, San Francisco • Aim: Knowledge-focused
Last updated Sep 04, 2026 00:00 UTC
-
A digital guide aims to help latinx cancer patients navigate genomic testing decisions
Knowledge-focused OngoingResearchers are testing an online decision support tool called Gene PilotLX to see if it helps Latinx cancer patients make informed choices about tumor genomic testing. Tumor genomic testing looks for genetic changes in a tumor that might guide treatment or reveal hereditary risk…
Sponsor: Fox Chase Cancer Center • Aim: Knowledge-focused
Last updated Sep 04, 2026 00:00 UTC
-
Researchers dig into past data to uncover M7824's hidden side effects
Knowledge-focused OngoingThis study reviews medical records from 232 adults with cancer who received the immunotherapy drug M7824. The goal is to create a complete list of side effects caused by the drug. By understanding these risks, doctors hope to prevent or reduce them in future cancer treatments.
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 02, 2026 00:00 UTC
-
500 cancer Patients' records reviewed to tame immunotherapy side effects
Knowledge-focused OngoingThis study looks back at the medical records of 500 children and adults with cancer who received immunotherapy at the National Cancer Institute. The goal is to understand the side effects, like inflammation and immune reactions, that can happen with these treatments. By learning …
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Sep 02, 2026 00:00 UTC
-
Blood test could spot rare nerve tumors years earlier in NF1 patients
Knowledge-focused By invitation onlyThis study is testing whether a blood test (liquid biopsy) can detect a rare but serious nerve tumor called MPNST earlier than current methods in adults with Neurofibromatosis Type 1 (NF1). Researchers will compare the timing of tumor detection by the blood test versus standard i…
Sponsor: David Miller • Aim: Knowledge-focused
Last updated Sep 02, 2026 00:00 UTC
-
Brain tumor breakthrough? simple blood test could replace risky biopsies
Knowledge-focused OngoingThis study tests whether a substance called 5-ALA, already used during brain surgery to make tumor cells glow, can also be detected in blood or urine. Researchers hope this 'liquid biopsy' could help diagnose and monitor glioblastoma, the most common and deadly brain tumor, witho…
Sponsor: Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta • Aim: Knowledge-focused
Last updated Aug 30, 2026 00:00 UTC
-
Cancer patients with COVID-19: new study tracks their journey
Knowledge-focused OngoingThis study follows nearly 1,900 cancer patients who tested positive for COVID-19. Researchers collect blood samples, medical records, and images to see how the virus impacts their cancer treatment and overall health. The goal is to learn which factors make COVID-19 more severe in…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 30, 2026 00:00 UTC
-
AI helps doctors remember what matters most to cancer patients
Knowledge-focused OngoingThis study tests whether an AI tool can accurately summarize serious illness conversations between doctors and cancer patients. Researchers will send these summaries to doctors caring for hospitalized patients with advanced cancer. The goal is to see if the summaries are accurate…
Sponsor: Dana-Farber Cancer Institute • Aim: Knowledge-focused
Last updated Aug 28, 2026 00:00 UTC
-
Cancer kids show surprising strength: study reveals growth, not just trauma
Knowledge-focused OngoingThis study looks at how children with cancer and their parents handle the emotional challenges of the disease. Instead of focusing only on negative effects like posttraumatic stress, researchers also explore positive changes, such as personal growth. The study compares these fami…
Sponsor: St. Jude Children's Research Hospital • Aim: Knowledge-focused
Last updated Aug 26, 2026 00:00 UTC
-
Researchers track Long-Term safety of experimental eye cancer treatment
Knowledge-focused By invitation onlyThis study is a long-term follow-up for 100 people who completed a previous trial of bel-sar, an experimental treatment for early choroidal melanoma (a type of eye cancer). Participants will not receive any new treatment but will be monitored for about 5 more years to check for s…
Sponsor: Aura Biosciences • Aim: Knowledge-focused
Last updated Aug 21, 2026 00:00 UTC
-
Can lifestyle choices after a stroke extend life and prevent a second one?
Knowledge-focused OngoingThis study follows 800 adults who have had their first ischemic stroke in Central Norway for up to 10 years. Researchers will track how physical activity, medication use, and control of blood pressure and cholesterol affect the risk of death, another stroke, or severe disability.…
Sponsor: Norwegian University of Science and Technology • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC
-
A simple screening program could transform cancer aftercare
Knowledge-focused OngoingThis trial tests whether a structured, nurse-led symptom screening program can increase the number of cancer survivors who are screened for distress and referred to supportive services. The program includes nurse training and regular feedback, and it will be rolled out across mul…
Sponsor: The University of Hong Kong • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC
-
Hidden risk: could opioid misuse be overlooked in cancer care?
Knowledge-focused PausedThis study aims to find out how often cancer patients treated with opioids for pain are at risk of misusing these medications. Researchers will use two screening questionnaires to assess misuse risk in 200 adult outpatients receiving opioids for cancer-related pain. The findings …
Sponsor: Rigshospitalet, Denmark • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
Can tracking a rare eye cancer pave the way for new treatments?
Knowledge-focused OngoingThis study follows people diagnosed with uveal melanoma, a rare eye cancer, over time to document the disease's natural course. Researchers will collect data on how the cancer progresses, including survival rates and whether it spreads. The goal is to build a detailed registry th…
Sponsor: Columbia University • Aim: Knowledge-focused
Last updated Aug 13, 2026 00:00 UTC
-
15-Year safety watch for cell therapy recipients
Knowledge-focused By invitation onlyThis study tracks the long-term safety of people who have already received a type of cell therapy called ADP adoptive cell therapy. Researchers will monitor up to 250 participants for up to 15 years after their last treatment to see if any delayed side effects occur. The goal is …
Phase 1 • Sponsor: USWM CT, LLC • Aim: Knowledge-focused
Last updated Aug 13, 2026 00:00 UTC
-
Gut bacteria may hold key to safer cancer immunotherapy
Knowledge-focused OngoingThis study is collecting stool and blood samples from 120 advanced cancer patients receiving immunotherapy combinations. Researchers want to see if the types of bacteria in the gut and certain immune markers can predict which patients will develop serious side effects. The goal i…
Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Aug 12, 2026 00:00 UTC
-
Do blood thinners help or hurt when cancer meets a clot?
Knowledge-focused OngoingThis study looks back at medical records of children and young adults with solid tumors or lymphoma who also have a tumor thrombus—a blood clot that forms in a vein due to tumor pressure or invasion. Researchers will gather data on who received blood thinners or procedures like s…
Sponsor: Children's Hospital Medical Center, Cincinnati • Aim: Knowledge-focused
Last updated Aug 07, 2026 00:00 UTC
-
Can natural remedies and cancer treatments mix safely? a new study investigates
Knowledge-focused OngoingThis study looks at how cancer patients use complementary and alternative medicine (CAM), such as herbal products and aromatherapy. Researchers will survey 500 patients and hold focus groups with 30-60 survivors to understand their needs, information sources, and any potential sa…
Sponsor: Jules Bordet Institute • Aim: Knowledge-focused
Last updated Aug 06, 2026 00:00 UTC
-
Chatbot could help families of kids with cancer understand genetic risks
Knowledge-focused By invitation onlyThis study is testing whether a chatbot can help parents of children with cancer learn about genetic risks and decide whether to get tested themselves. The chatbot provides education and support as an alternative to speaking with a genetic counselor. The goal is to make it easier…
Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Knowledge-focused
Last updated Jul 31, 2026 00:00 UTC
-
Can a Finger-Prick replace the lab draw? a device puts accuracy to the test
Knowledge-focused PausedThis study is testing whether a new device called Liberty can accurately measure blood counts from a finger-prick sample compared to standard venous blood draws. Researchers will collect paired capillary and venous blood samples from healthy volunteers and cancer patients receivi…
Sponsor: Entia Ltd • Aim: Knowledge-focused
Last updated Jul 31, 2026 00:00 UTC
-
Cancer clinics study how to spot Patients' hidden struggles
Knowledge-focused By invitation onlyThis study looks at how community cancer clinics screen for health-related social needs, like help with housing, food, or transportation. Researchers will work with 144 clinic staff to understand what helps or hinders screening. The goal is to create custom plans to make screenin…
Sponsor: Wake Forest University Health Sciences • Aim: Knowledge-focused
Last updated Jul 26, 2026 00:00 UTC
-
Island hopping for cancer care: first study maps Survivors' journeys across six caribbean nations
Knowledge-focused By invitation onlyThis study follows 900 cancer survivors from six small island nations (Antigua, Dominica, Grenada, Saint Kitts, Saint Lucia, and Saint Vincent) to understand how traveling overseas for cancer treatment affects their health and social support. Researchers will compare those who se…
Sponsor: Vaughan A. Lewis Institute for Research and Innovation • Aim: Knowledge-focused
Last updated Jul 12, 2026 00:00 UTC
-
Smartwatches for cancer survivors: a new way to track symptoms?
Knowledge-focused OngoingThis study looks at whether cancer survivors can use a smartwatch and a phone app to regularly report their symptoms and activity levels. Fifty adults who have finished cancer treatment and have stable disease will wear a smartwatch for about four months and fill out weekly quest…
Sponsor: Laura Longshaw • Aim: Knowledge-focused
Last updated Jul 04, 2026 00:00 UTC
-
Can coaching caregivers improve cancer Decision-Making?
Knowledge-focused OngoingThis study tests a training program called CASCADE for family caregivers of people with advanced cancer. The goal is to see which parts of the training best help caregivers support patients in making medical decisions. 256 caregivers are taking part in different combinations of c…
Sponsor: University of Alabama at Birmingham • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
Can a simple card keep cancer patients safer?
Knowledge-focused OngoingThis study tests whether giving cancer patients a drug vigilance card helps them avoid medication errors and interactions when seeing other doctors. One hundred patients on oral chemotherapy or targeted therapies at Limoges University Hospital will use the card. Researchers will …
Sponsor: University Hospital, Limoges • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
Blood test could spare brain tumor patients from repeated surgeries
Knowledge-focused OngoingThis study investigates whether a simple blood test can help diagnose and monitor low-grade gliomas, a type of slow-growing brain tumor. Researchers will collect blood samples from 50 patients undergoing brain surgery to look for circulating tumor cells and other markers. The goa…
Sponsor: University Hospital, Montpellier • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
Blood markers could spot hidden skin cancer return
Knowledge-focused OngoingThis study follows 35 people with Merkel cell carcinoma, a rare and aggressive skin cancer, to see if two blood markers (T-antigen antibodies and miR-375) can detect when the cancer comes back. Currently, follow-up relies on physical exams and scans, which may miss early recurren…
Sponsor: University Hospital, Tours • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:08 UTC
-
Keytruda immune response trial aims to unlock cancer clues
Knowledge-focused OngoingThis phase 2 trial is testing how the immunotherapy drug pembrolizumab (Keytruda) changes immune-related genes and biomarkers in people with advanced solid tumors like head and neck cancer, triple-negative breast cancer, ovarian cancer, and melanoma. Researchers will analyze bloo…
Phase 2 • Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC
-
Could Symptom-Triggered scans replace routine MRIs for brain cancer?
Knowledge-focused By invitation onlyThis study tests whether using an app for patients to report symptoms can guide when to do MRI scans, instead of following a fixed schedule. It involves 20 adults with newly diagnosed glioblastoma. The goal is to see if this approach is feasible and acceptable, not yet to prove i…
Sponsor: King's College Hospital NHS Trust • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC
-
Cancer patients get help planning families in new study
Knowledge-focused OngoingThis study tested a program to help cancer patients understand their fertility risks and get the right care. It included 434 women aged 15-55 with a new cancer diagnosis. The program aimed to connect them with specialists for pregnancy planning or fertility preservation based on …
Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
New web tool aims to help young cancer patients plan for family future
Knowledge-focused OngoingThis study tests a web-based tool called REFLECT, designed to help adolescent and young adult cancer patients learn about fertility and genetic risks for future children. Sixteen participants who have had cancer care at Moffitt Cancer Center will use the tool and rate how easy an…
Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:37 UTC
-
Cancer imaging study pulled before starting
Knowledge-focused CancelledThis study aimed to test a new device that rotates patients horizontally to take CT images for guiding radiation therapy in cancer patients. It was designed for adults with certain cancers, but the trial was withdrawn before enrolling anyone. The goal was to see if the images wer…
Early phase 1 • Sponsor: University of Sydney • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:35 UTC
-
One workout could boost cancer fighters?
Knowledge-focused OngoingThis study compares how a single bout of exercise changes immune cells and inflammation in cancer patients undergoing chemotherapy and in healthy people of the same age. Researchers will measure natural killer cells and other immune markers before and after exercise. The goal is …
Phase 2 • Sponsor: Universität Duisburg-Essen • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
Spine registry aims to unlock secrets of tumors and disorders
Knowledge-focused PausedThis study is a registry that collects medical records, quality-of-life questionnaires, and tissue samples from 900 people with spine tumors or other spine disorders. The goal is to learn more about these conditions to guide better treatment in the future. Participants must be be…
Sponsor: Duke University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:30 UTC
-
Patients claim cannabis stops tumor growth – scientists investigate
Knowledge-focused OngoingThis study looks at medical records of 50 cancer patients who say cannabis helped stop their tumor from growing or shrank it. Researchers want to see if there is real evidence behind these claims. The goal is to gather information, not to test a new treatment.
Sponsor: HealthPartners Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:30 UTC
-
Brain zap aftermath: can we map and avoid memory loss?
Knowledge-focused OngoingThis study tracks 80 patients with brain tumors (metastases or meningiomas) who receive stereotactic radiosurgery. Researchers use memory tests and quality-of-life questionnaires before treatment and every 3 months for a year to see if and how brain function changes. By comparing…
Sponsor: University of Nottingham • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Smartwatches track cancer symptoms at home
Knowledge-focused By invitation onlyThis study explores whether wearable devices, like smartwatches, can help monitor symptoms in cancer survivors. Twenty participants will wear a sensor-packed device that tracks temperature, heart rate, sleep, and activity. Researchers will see how many people agree to use the wea…
Sponsor: University of Alabama at Birmingham • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Pregnancy DNA test may spot cancer in Moms-to-Be
Knowledge-focused By invitation onlyThis study looks at whether the standard blood test given to pregnant women to screen for fetal conditions can also detect signs of cancer in the mother. Researchers will analyze DNA from 300 pregnant women with known or newly diagnosed cancer to identify specific chromosomal pat…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Lifestyle coaching aims to boost activity in cancer survivors
Knowledge-focused OngoingThis study tests whether personalized telehealth coaching can help young adult cancer survivors become more physically active and improve their diet. Researchers are enrolling 374 survivors aged 18-54 who are not very active. Participants receive one-on-one sessions with a clinic…
Sponsor: Fred Hutchinson Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:08 UTC
-
500 eye melanoma patients share their quality of life journey
Knowledge-focused OngoingThis study follows 500 people diagnosed with uveal melanoma (a rare eye cancer) for five years after treatment. Participants fill out questionnaires about their physical and mental well-being, treatment side effects, and decision-making. The goal is to learn how different treatme…
Sponsor: Leiden University Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:07 UTC
-
New study aims to improve cancer care for seniors
Knowledge-focused By invitation onlyThis study looks at whether training and support can help cancer clinics give special check-ups (called geriatric assessments) to patients aged 65 and older who are starting a new cancer treatment. These check-ups help find and address health issues, support needs, and daily life…
Sponsor: Wake Forest University Health Sciences • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:05 UTC
-
New Full-Body PET scanner promises faster scans, less radiation
Knowledge-focused OngoingThis study compares a new total body PET scanner (Omni TB) with conventional PET in 25 adult cancer patients. The new scanner can image the whole body at once with higher sensitivity, potentially allowing shorter scan times and lower radiation doses. Researchers will assess wheth…
Sponsor: Peter MacCallum Cancer Centre, Australia • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:05 UTC
-
Tracking childhood cancer survivors for decades to improve their future health
Knowledge-focused OngoingThis long-term study follows 5,000 childhood cancer survivors who had a stem cell transplant or treatment for leukemia or solid tumors. Researchers collect health updates and quality-of-life questionnaires over 20+ years to understand late effects of therapy. The goal is to reduc…
Sponsor: Children's Oncology Group • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:04 UTC
-
Spine surgery showdown: robot vs. human hand – which is safer?
Knowledge-focused OngoingThis study looks at three ways surgeons place screws in the spine during surgery: using a robot, using a navigation system, or doing it by hand. The goal is to see which method leads to fewer screws needing to be fixed in a second surgery within the first year. About 932 adults w…
Sponsor: Marc Schröder • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:02 UTC
-
Pedaling against cancer: exercise may boost immunotherapy
Knowledge-focused OngoingThis small pilot study is testing whether a 30-minute stationary bike ride on the same day as immunotherapy can help the treatment work better for people with skin cancers like melanoma. The study involves 12 patients and focuses on whether this exercise plan is practical and saf…
Sponsor: AdventHealth Translational Research Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:00 UTC
-
Skin sensor could alert doctors to rising pain in cancer and COPD patients
Knowledge-focused OngoingThis study tests whether a wearable skin sensor can tell the difference between mild, moderate, and severe pain in 37 adults with cancer or COPD. Participants wear the device for up to a week and report their pain levels. The goal is to create an algorithm that alerts caregivers …
Sponsor: Copenhagen University Hospital, Hvidovre • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:03 UTC
-
Neuro-Patch under the microscope: Real-World surgery study launched
Knowledge-focused OngoingThis study is observing 328 adults who receive a Neuro-Patch during brain or spine surgery to repair the protective lining around the brain or spinal cord. Researchers are tracking complications and how easy the patch is for surgeons to use. The goal is to gather real-world data …
Sponsor: Aesculap AG • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:03 UTC
-
Tumor DNA study aims to unlock secrets of drug resistance
Knowledge-focused OngoingThis study collects tumor tissue, blood, and saliva from 2500 people with various solid cancers to analyze their genetic makeup. The goal is to understand why some tumors become resistant to targeted therapies. Samples may also be grown in special mice to study how genetics affec…
Sponsor: Fondazione del Piemonte per l'Oncologia • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:03 UTC
-
Study probes Patients' minds, not their tumors
Knowledge-focused OngoingThis study looks at how older adults (65+) with cancer understand their illness and what they value in life before and after a major operation. Researchers will interview 100 patients to learn about their awareness, expectations, and decision-making. No new drug or treatment is b…
Sponsor: Tomas Bata Hospital, Czech Republic • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:02 UTC
-
Lab test could match cancer patients to the right drugs
Knowledge-focused OngoingThis study tests a new lab method called OPTin that helps doctors pick the most effective drugs for people with advanced or hard-to-treat solid tumors. About 200 adults will provide a small tumor sample for testing, then receive either a drug chosen by OPTin or one selected by th…
Sponsor: China Medical University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC
-
Racial gap in cancer treatment? new study investigates immunotherapy outcomes
Knowledge-focused OngoingThis study is collecting blood, saliva, and health information from 2,100 Black and White cancer patients who are receiving immunotherapy (drugs that help the immune system fight cancer). The goal is to see if there are differences in side effects and how well the treatment works…
Sponsor: University of Rochester NCORP Research Base • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC
-
New study aims to predict and prevent dangerous drug reactions
Knowledge-focused OngoingThis study looks at whether combining genetic tests, regular drug level checks, and careful medication reviews can help doctors prescribe the right drugs and avoid harmful side effects. It involves 450 adults with cancer and children with chronic inflammatory diseases. The goal i…
Sponsor: Direzione centrale salute, politiche sociali e disabilità • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC
-
New MRI-Guided radiotherapy machine put to the test
Knowledge-focused OngoingThis study checks how well a new MRI-guided radiotherapy machine works and how it fits into daily hospital routines. About 150 adults with solid tumors will take part. The goal is to see if the machine can be used smoothly for treatment, not to test a new cure.
Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:11 UTC
-
1000 brain tumor Patients' records reviewed to see what worked
Knowledge-focused OngoingThis study is not testing a new treatment. Instead, researchers are reviewing medical records from 1000 adults with recurrent malignant gliomas (aggressive brain tumors) to see how well past chemotherapy and targeted therapies worked. The goal is to learn which treatments are lin…
Sponsor: Blokhin's Russian Cancer Research Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:10 UTC
-
Blood test could replace brain surgery for tumor tracking
Knowledge-focused OngoingThis study aims to develop a liquid biopsy—a blood test—to detect tumor DNA in patients with high-grade gliomas, an aggressive type of brain cancer. Researchers will collect blood samples from 70 patients before and after standard radiotherapy to see if they can measure tumor cha…
Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:10 UTC
-
Global study reviews brain metastasis treatments in colorectal cancer patients
Knowledge-focused OngoingThis observational study looks back at 700 patients from 15 hospitals in 2 countries to compare local treatments like surgery and radiation for brain metastases that spread from colorectal cancer. Researchers will track how long patients live and how long it takes for brain tumor…
Sponsor: Blokhin's Russian Cancer Research Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:10 UTC
-
MRI-Guided radiation: a sharper weapon against cancer?
Knowledge-focused OngoingThis study is testing a new radiation technique that uses real-time MRI scans to target cancer more precisely. About 377 adult cancer patients will receive this treatment and have extra scans and quality-of-life surveys. The goal is to see if this approach improves tumor control …
Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:10 UTC
-
Scientists dig into past cases to find best brain tumor treatments for stomach cancer patients
Knowledge-focused OngoingThis study reviews medical records from 230 adults with stomach or esophagus cancer that spread to the brain. Researchers want to see which local treatments (like surgery or radiation) worked best and how long patients lived. The goal is to gather information to help doctors make…
Sponsor: Blokhin's Russian Cancer Research Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:10 UTC
-
Can we track brain health in older cancer patients?
Knowledge-focused OngoingThis study looks at whether it's possible to track memory and thinking changes in adults aged 65 and older who are starting a new type of cancer treatment called immune checkpoint inhibitors. Thirty participants will take simple memory and concentration tests every six weeks for …
Sponsor: Our Lady's Hospice and Care Services • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:09 UTC
-
Massive data hunt aims to unlock secrets of spine metastases
Knowledge-focused OngoingThis study is a registry that gathers detailed information from about 960 adults with metastatic spine tumors (cancer that has spread to the spine from elsewhere). Researchers collect data on patients' health, treatments, symptoms, and quality of life over time. The goal is to be…
Sponsor: AO Innovation Translation Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:08 UTC
-
Blood test could help spot brain tumor growth vs. treatment side effects
Knowledge-focused By invitation onlyThis study is part of a larger trial testing an oxygen-boosting drug called NanO2 in people with glioblastoma, a serious brain cancer. Researchers will analyze blood samples from 40 patients to find markers that show how low oxygen levels in the tumor affect the disease. They als…
Sponsor: NuvOx LLC • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:06 UTC
-
7,000 tumor samples analyzed to uncover Cancer's hidden support system
Knowledge-focused OngoingThis study looks at the stroma—the supportive tissue around tumors—in both benign and malignant growths. Researchers will examine 7,000 patient samples collected since 2000 at Brest University Hospital. The goal is to count non-tumor cells and measure matrix percentages in tumor …
Sponsor: University Hospital, Brest • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:04 UTC
-
Lung cancer in the brain: which treatment works best?
Knowledge-focused OngoingThis study looks at patients with non-small-cell lung cancer that has spread only to the brain (fewer than 5 spots). Researchers will review different treatment strategies used at two hospitals to see which leads to longer survival without the disease getting worse. The goal is t…
Sponsor: University Hospital, Bordeaux • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:02 UTC
-
New dosing method for Kids' cancer drug aims to reduce side effects
Knowledge-focused OngoingThis study looks at a new method for giving the cancer drug vincristine to infants and young children. The goal is to see if this new way of calculating the dose leads to similar drug levels in the blood as the standard method used in older children. About 83 children up to 12 ye…
Sponsor: Children's Oncology Group • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:02 UTC
-
Telehealth under the microscope: did virtual cancer care hold up during COVID?
Knowledge-focused By invitation onlyThis study looks at how doctors and nurses in radiation oncology used telehealth instead of in-person visits during the COVID-19 pandemic. Researchers will survey 1,000 healthcare providers at Duke Cancer Center to understand their experiences and challenges. They will also track…
Sponsor: Duke University • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:02 UTC
-
Can less radiation treat eye cancer just as well?
Knowledge-focused OngoingThis study tracks 42 people with ocular melanoma who received radiation therapy via eye plaque brachytherapy. Researchers want to see if using lower radiation doses can still keep the cancer from coming back while reducing harmful side effects. The goal is to find the safest effe…
Sponsor: Duke University • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:02 UTC
-
Can a short video help cancer patients get better palliative care?
Knowledge-focused OngoingThis study tests whether an educational video can help adults with serious cancer understand and use palliative care. 172 participants will either receive standard care plus brochures, or standard care plus a tailored video and extra materials. Researchers will track knowledge, a…
Sponsor: Tulane University • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:01 UTC
-
Fiber fix: diet study hopes to boost cancer immunotherapy
Knowledge-focused OngoingThis study looks at whether eating a high-fiber diet can change the gut bacteria of people with advanced melanoma who are receiving standard immunotherapy. About 50 participants will be randomly assigned to either a high-fiber or a healthy control diet for a set period. The main …
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:00 UTC
-
Italy launches massive genetic database to match cancer patients with better treatments
Knowledge-focused OngoingThis observational study aims to create a national registry of genetic mutations found in advanced solid tumors. By collecting data from over 2,000 Italian patients, researchers hope to improve access to innovative therapies. The study does not test a new treatment but gathers in…
Sponsor: Federation of Italian Cooperative Oncology Groups • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:00 UTC
-
AI reads brain scans to unlock lung cancer secrets without surgery
Knowledge-focused By invitation onlyThis study looks at whether a computer model can analyze routine brain MRI scans to predict if a lung cancer that has spread to the brain has certain genetic changes (EGFR or ALK). The goal is to see if this noninvasive method can replace the need for a brain tumor biopsy to guid…
Sponsor: Ming Yang • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:00 UTC
-
New imaging technique could reveal how brain tumors hide from the immune system
Knowledge-focused OngoingThis study looks at how aggressive brain tumors (gliomas) suppress the immune system. Researchers will use special MRI and PET scans to track immune cells and iron levels in the tumor. The goal is to find better ways to measure immune suppression, which could help develop new tre…
Sponsor: Istituto Oncologico Veneto IRCCS • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:13 UTC
-
Withdrawn study sought to understand when lymphoma and cancer strike together
Knowledge-focused CancelledThis study was designed to look back at medical records of people in Picardy, France, who were diagnosed with both lymphoma and another cancer within six months between 2007 and 2012. The goal was to see if these cases were more common than expected and to describe patient charac…
Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:11 UTC
-
Pandemic delays led to fewer cancer diagnoses, study of 438,000 cases shows
Knowledge-focused OngoingThis study looks at how the COVID-19 pandemic changed the number of new cancer cases in Bavaria, Germany. Researchers analyzed data from 438,000 adults diagnosed with cancer between 2018 and 2023 to see if certain regions or cancer types were more affected. The goal is to underst…
Sponsor: Bavarian Cancer Registry • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:08 UTC
-
Young cancer survivors face hidden financial toll
Knowledge-focused By invitation onlyThis study looks at financial problems (called 'financial toxicity') in young adults aged 18-39 who have finished cancer treatment. Researchers will survey 300 participants to measure money stress during and after therapy, and find out what factors make it worse. The goal is to l…
Sponsor: University Medical Center Goettingen • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:08 UTC
-
Can laughter yoga and art therapy ease cancer distress?
Knowledge-focused By invitation onlyThis study looks at how mind-body therapies—like mindfulness, laughter yoga, and art therapy—affect the quality of life and emotional distress of 150 cancer patients. Participants will fill out questionnaires before and after an 8-week program. The goal is to see if these therapi…
Sponsor: La Tour Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:06 UTC
-
Stem cells may unlock mystery of chemo-related heart damage
Knowledge-focused OngoingThis study uses stem cells made from patients' own cells to understand why some people develop severe heart or lung side effects from certain chemotherapy drugs. Researchers will compare cells from patients who had extreme toxicity to those who did not. The goal is to uncover the…
Sponsor: University Medical Center Groningen • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:03 UTC
-
Brain tumor patients help scientists map the mind
Knowledge-focused OngoingThis study looks at how brain tumors change the way different parts of the brain connect and communicate. Researchers will use brain scans and electrical recordings from 30 adults scheduled for tumor removal surgery. The goal is to better understand brain plasticity and improve f…
Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:01 UTC
-
Eye cancer survivors: does anesthesia affect the brain?
Knowledge-focused By invitation onlyThis study looks at how cancer treatment and multiple rounds of anesthesia affect thinking skills, emotions, and quality of life in people who survived retinoblastoma (a rare eye cancer) or were at risk for it. Researchers will test memory, attention, and other brain functions in…
Sponsor: Amsterdam University Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:01 UTC
-
Brain tumor imaging study pulled before it began
Knowledge-focused CancelledThis study was designed to see if a special MRI technique could help surgeons map important brain pathways in people with malignant brain tumors. It was withdrawn before any participants were enrolled, so no data or results were collected. The goal was to compare the MRI findings…
Sponsor: GCS Ramsay Santé pour l'Enseignement et la Recherche • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:01 UTC
-
New online tool aims to help older cancer patients get better treatment plans
Knowledge-focused OngoingThis study is testing an online questionnaire called CHAMP that older adults with cancer can fill out before their doctor's visit. The tool asks about daily function, memory, mood, and support to help doctors tailor cancer treatment. Researchers want to see if the tool is easy to…
Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:00 UTC
-
Could your genes raise your lung cancer risk? new study investigates
Knowledge-focused OngoingThis study looks at whether certain inherited gene changes (EGFR mutations) increase the risk of lung cancer, especially in people who never smoked. Researchers collect saliva from cancer patients with a specific tumor mutation (T790M) to find these inherited changes. They also o…
Sponsor: Dana-Farber Cancer Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:59 UTC
-
Gut bacteria could be key to better cancer immunotherapy
Knowledge-focused OngoingThis study looks at how the diversity of bacteria in the gut might affect how well immunotherapy works in people with solid tumors. Researchers will collect stool and blood samples from 70 cancer patients starting immunotherapy to track changes in gut bacteria and immune markers.…
Sponsor: Fondazione IRCCS Policlinico San Matteo di Pavia • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:57 UTC
-
Scientists hunt for immune clues in glioblastoma patients
Knowledge-focused PausedThis study collects blood and bone marrow samples from 40 adults with newly diagnosed glioblastoma to track changes in immune cells over time. Researchers aim to understand how the immune system responds to the tumor and standard treatments. The goal is to gather foundational dat…
Sponsor: Duke University • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:57 UTC
-
New study tracks ovarian health after chemo in young women
Knowledge-focused OngoingThis study follows 196 women aged 11-35 who are receiving chemotherapy for cancer. Researchers measure hormone levels and ovarian follicles before, during, and after treatment to see how the ovaries are affected. The goal is to better understand the risk of early menopause and fe…
Sponsor: University of Pennsylvania • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:56 UTC
-
Cancer Patients' vaccine response under microscope
Knowledge-focused OngoingThis study looks at how well cancer patients respond to common vaccines like flu, COVID-19, and shingles. Researchers will measure antibody levels before and after vaccination in 250 adults with cancer. The goal is to understand immune responses in this group, not to test a new t…
Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:55 UTC
-
Techs to the rescue: new study tests if radiology staff can catch cancer treatment side effects
Knowledge-focused OngoingThis study tests whether adding a weekly check-in with a radiology technician (called a MERM) to standard doctor visits can better detect side effects in brain tumor patients receiving proton therapy. About 92 adults with brain or upper airway tumors will be randomly assigned to …
Sponsor: Centre Francois Baclesse • Aim: Knowledge-focused
Last updated Jun 26, 2026 17:51 UTC
-
New algorithm aims to catch ovarian damage early in young cancer survivors
Knowledge-focused CancelledThis study was designed to see if a new monitoring algorithm could detect early signs of ovarian damage in women and girls who had cancer treatment. Researchers planned to compare a group using the new algorithm with a group that received standard care. However, the study was wit…
Sponsor: University of Colorado, Denver • Aim: Knowledge-focused
Last updated Jun 26, 2026 17:42 UTC
-
Can yearly MRIs catch second cancers in retinoblastoma survivors?
Knowledge-focused OngoingThis study looks at whether yearly MRI scans can find new head and neck or brain cancers early in people who had hereditary retinoblastoma and were treated with radiation. Researchers will follow 88 participants for 10 years to see if early detection leads to better surgery outco…
Sponsor: Institut Curie • Aim: Knowledge-focused
Last updated Jun 26, 2026 16:56 UTC
-
Which anesthetic best reveals seizure spots in the brain?
Knowledge-focused OngoingThis study compares two anesthetic drugs, fentanyl and ketamine, to see which one better helps surgeons find seizure-causing brain tissue during epilepsy surgery in children. Eighty-eight children aged 2-18 with brain tumors and epilepsy will receive one of the drugs during surge…
Phase 3 • Sponsor: Children's Cancer Hospital Egypt 57357 • Aim: Knowledge-focused
Last updated Jun 26, 2026 15:56 UTC
-
Simple blood test may reveal how far cancer has spread
Knowledge-focused OngoingThis study is checking if two substances in the blood, called IGF-1 and IGF-1Ec, are linked to how much cancer is in the body. Researchers will measure these levels in 100 adults with solid tumors and compare them to tumor size, stage, and spread. The goal is to see if these mark…
Sponsor: Çanakkale Onsekiz Mart University • Aim: Knowledge-focused
Last updated Jun 26, 2026 13:18 UTC